Document:

exv10w3

Exhibit 10.3

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE CONFIDENTIAL PORTIONS
HAVE BEEN REDACTED AND ARE DENOTED BY A TRIPLE ASTERISK (***). THE CONFIDENTIAL PORTIONS HAVE BEEN
SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

EXECUTION COPY

DISTRIBUTION AND SUPPLY AGREEMENT

BETWEEN

PURDUE PHARMA L.P.

AND

KV PHARMACEUTICAL COMPANY

DATED AS OF

JUNE 9, 2009

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE I DEFINITIONS; INTERPRETATIONS	 	 	1	 
	 	1.1   	 	 	Definitions
	 	 	1	 
	 	1.2	 	 	Interpretations
	 	 	7	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE II DISTRIBUTORSHIP/APPOINTMENT	 	 	8	 
	 	2.1	 	 	Appointment/Authorization
	 	 	8	 
	 	2.2	 	 	Limitation on Rights
	 	 	10	 
	 	2.3	 	 	Distributor Obligations
	 	 	11	 
	 	2.4	 	 	Meetings
	 	 	11	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE III GENERAL TERMS OF SUPPLY	 	 	11	 
	 	3.1	 	 	Sales and Supply of Product
	 	 	11	 
	 	3.2	 	 	Shipment
	 	 	12	 
	 	3.3	 	 	Storage and Shipments
	 	 	13	 
	 	3.4	 	 	Product Rejection
	 	 	13	 
	 	3.5	 	 	Quality Control; Change in Specifications
	 	 	14	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE IV PAYMENTS AND REPORTS	 	 	14	 
	 	4.1	 	 	Payment to Purdue
	 	 	14	 
	 	4.2	 	 	Reporting Obligations and Audit Rights
	 	 	15	 
	 	4.3	 	 	Mode of Payment
	 	 	16	 
	 	4.4	 	 	Records Retention
	 	 	16	 
	 	4.5	 	 	Certificates; Audit
	 	 	17	 
	 	4.6	 	 	Taxes
	 	 	17	 
	 	4.7	 	 	Late Payments
	 	 	17	 
	 	4.8	 	 	Notice of Destruction of Records
	 	 	18	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE V COVENANTS	 	 	18	 
	 	5.1	 	 	Mutual Covenants
	 	 	18	 
	 	5.2	 	 	Purdue Covenants
	 	 	18	 
	 	5.3	 	 	Distributor Covenants
	 	 	19	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE VI REPRESENTATIONS AND WARRANTIES	 	 	21	 
	 	6.1	 	 	Representations and Warranties of Both Parties
	 	 	21	 
	 	6.2	 	 	Additional Purdue Representations and Warranties
	 	 	22	 
	 	6.3	 	 	Additional Distributor Representations and Warranties
	 	 	23	 
	 	6.4	 	 	No Reliance by Third Parties
	 	 	23	 
	 	6.5	 	 	Disclaimer of Warranties
	 	 	23	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE VII INTELLECTUAL PROPERTY	 	 	24	 
	 	7.1	 	 	Limited Intellectual Property Rights
	 	 	24	 

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

i

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	 	 	 	 	 
	 	 	 	 
	 	7.2	 	 	No Improvements
	 	 	24	 
	 	7.3	 	 	Improvements
	 	 	24	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE VIII INDEMNIFICATION; LIMITATIONS ON LIABILITY	 	 	24	 
	 	8.1	 	 	Purdue Indemnity
	 	 	25	 
	 	8.2	 	 	Distributor Indemnity
	 	 	25	 
	 	8.3	 	 	Procedure for Indemnification
	 	 	25	 
	 	8.4	 	 	Limitations on Liability
	 	 	27	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE IX COMPLIANCE WITH GOVERNMENTAL AUTHORITY REGULATIONS	 	 	27	 
	 	9.1	 	 	Governmental Authority Communications
	 	 	27	 
	 	9.2	 	 	Governmental and Regulatory Inspections
	 	 	28	 
	 	9.3	 	 	Quality Agreement
	 	 	29	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE X CONFIDENTIALITY	 	 	29	 
	 	10.1	 	 	Confidentiality
	 	 	29	 
	 	10.2	 	 	Authorized Disclosure
	 	 	29	 
	 	10.3	 	 	Remedies
	 	 	30	 
	 	10.4	 	 	Return of Confidential Information
	 	 	30	 
	 	10.5	 	 	Unauthorized Use
	 	 	30	 
	 	10.6	 	 	Exclusive Property
	 	 	30	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE XI TERM; TERMINATION	 	 	31	 
	 	11.1	 	 	Term
	 	 	31	 
	 	11.2	 	 	Termination
	 	 	31	 
	 	11.3	 	 	Effect of Termination
	 	 	32	 
	 	11.4	 	 	Accrued Rights; Surviving Obligations
	 	 	32	 
	 	 	 	 	 
	 	 	 	 
	ARTICLE XII MISCELLANEOUS PROVISIONS	 	 	34	 
	 	12.1	 	 	Force Majeure
	 	 	34	 
	 	12.2	 	 	Notice
	 	 	34	 
	 	12.3	 	 	Assignment
	 	 	35	 
	 	12.4	 	 	No Waiver
	 	 	35	 
	 	12.5	 	 	Injunction
	 	 	36	 
	 	12.6	 	 	Governing Law
	 	 	36	 
	 	12.7	 	 	Entirety of Agreement
	 	 	36	 
	 	12.8	 	 	Public Announcements
	 	 	36	 
	 	12.9	 	 	Relationship of the Parties
	 	 	37	 
	 	12.10	 	 	Non-Solicitation of Employees
	 	 	37	 
	 	12.11	 	 	Severability
	 	 	37	 
	 	12.12	 	 	Books and Records
	 	 	37	 
	 	12.13	 	 	Expenses
	 	 	37	 
	 	12.14	 	 	No Third Party Beneficiary
	 	 	38	 

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

ii

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page	 
	 	 	 	 	 
	 	 	 	 
	 	12.15	 	 	Further Actions
	 	 	38	 
	 	12.16	 	 	Counterparts; Facsimile Signatures
	 	 	38	 
	 	12.17	 	 	Headings
	 	 	38	 

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

iii

 

SCHEDULES

	 	 	 
	Schedule 1.1A

	 	Branded Products
	Schedule 1.1B

	 	Cost of Goods Sold
	Schedule 1.1C

	 	Products
	Schedule 1.1D

	 	Risk Management Program
	Schedule 3.1.1

	 	Supply Amount
	Schedule 3.1.4

	 	Initial Label; Indicia
	Schedule 3.3.3

	 	Shipping Location
	Schedule 3.3.5A

	 	Form of Certificate of Analysis
	Schedule 3.3.5B

	 	Form of Certificate of Compliance

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

iv

 

DISTRIBUTION AND SUPPLY AGREEMENT

     THIS
DISTRIBUTION AND SUPPLY AGREEMENT is entered into as of June 9, 2009 between Purdue
Pharma L.P., a Delaware limited partnership (“Purdue”), and KV Pharmaceutical Company, a
Delaware corporation (“Distributor”).

PRELIMINARY STATEMENTS

     A. Purdue, directly or indirectly through its Affiliates, manufactures, distributes, markets
and sells the Branded Products in the Territory.

     B. Subject to the terms and conditions of this Agreement, Purdue desires to engage Distributor
as an authorized, non-exclusive distributor to distribute, market and sell the Products in the
Territory.

     C. Subject to the terms and conditions of this Agreement, Distributor desires to obtain from
Purdue the right to distribute, market and sell the Products in the Territory.

     NOW, THEREFORE, in consideration of the foregoing and of the terms, conditions, agreements and
covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereto agree as follows:

ARTICLE I

DEFINITIONS; INTERPRETATIONS

     1.1 Definitions. For purposes of this Agreement:

     “’042 Patent” means United States Patent 5,508,042.

     “Affiliate” means, as to any Party, any person, firm, trust, partnership, corporation,
company or other entity or combination thereof, which directly or indirectly (i) controls a Party,
(ii) is controlled by a Party or (iii) is under common control with a Party. The terms “control”
and “controlled” mean (x) ownership of 50% or more, including ownership by trusts with
substantially the same beneficial interests, of the voting and equity rights of such person, firm,
trust, partnership, corporation, company or other entity or combination thereof or (y) the power to
direct the management of such person, firm, trust, partnership, corporation, company or other
entity or combination thereof. Notwithstanding the above, for purposes of this Agreement, The
Purdue Frederick Company Inc., a New York corporation (d/b/a The Purdue Frederick Company) shall
not be considered an Affiliate of Purdue.

     “Agreement” means this Distribution and Supply Agreement, together with all
appendices, exhibits and schedules attached hereto, as the same may be amended or supplemented from
time to time, by written agreement of the Parties.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

     “ANDA” means an abbreviated new drug application seeking approval for a drug under
Section 505(j) of the Federal Food, Drug and Cosmetic Act, and the rules, regulations and
guidelines promulgated thereunder, and FDA’s implementing regulations, including all
amendments and supplements, filed pursuant to the requirements of the FDA, including all
documents, data and other information concerning such drug submitted as part of the application or
in amendments or supplements thereto that are necessary for FDA approval to market the drug in the
Territory.

     “API” means active pharmaceutical ingredient.

     “Bankruptcy Code” has the meaning set forth in Section 11.2.2.

     “Bottle” means a bottle of Product containing 100 tablets.

     “Branded Product” means any of Purdue’s branded products listed on Schedule
1.1A.

     “Bundled Product” means a Product offered or sold in combination with one or more of
Distributor’s other products.

     “Business Day” means any day other than a Saturday, Sunday or other day on which banks
in the City of New York are authorized or required by Law to close.

     “Certificate of Analysis” means the certificate of analysis for each Product in the
form attached hereto as Schedule 3.3.5A.

     “Certificate of Compliance” means the certificate of compliance for each Product in
the form attached hereto as Schedule 3.3.5B.

     “Change of Control” has the meaning set forth in Section 12.3.

     “Commercially Reasonable Efforts” means, with respect to a given goal, the efforts,
consistent with the practice of comparable pharmaceutical companies with respect to a
pharmaceutical product owned by it or to which it has rights of comparable market potential at a
similar stage in its product life (taking into account the competitiveness of the marketplace, the
proprietary position of the applicable active ingredient, the regulatory structure involved, and
the profitability of the product), that a reasonable Person in the position of the obligor would
use so as to achieve that goal as expeditiously as possible.

     “Confidential Information” means all secret, confidential or proprietary information
or data, whether provided in written, oral, graphic, video, computer or other form, provided by one
Party or its Affiliates or representatives (the “Disclosing Party”) to the other Party or
its Affiliates or representatives (the “Receiving Party”) pursuant to this Agreement or
generated pursuant to this Agreement, including any information or reports the Receiving Party may
generate, the terms of this Agreement and any other materials that have not been made available by
the Disclosing Party

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

2

 

to the general public. Notwithstanding the foregoing sentence, Confidential
Information will not include any specific portion of any information or materials that:

          (a) were already known to the Receiving Party (other than under an obligation of
confidentiality) at the time of disclosure by the Disclosing Party to the extent such Receiving
Party has documentary evidence to that effect;

          (b) were generally available to the public at the time of their disclosure to the Receiving
Party;

          (c) became generally available to the public after their disclosure or development, as the
case may be, other than through any act or omission of a Party in breach of such Party’s
confidentiality obligations under this Agreement;

          (d) were disclosed to a Receiving Party, other than under an obligation of confidentiality, by
a Third Party who had no obligation to the Disclosing Party not to disclose such information to
others; or

          (e) are independently developed by employees, authorized agents or independent contractors of
the Receiving Party without use of, reference to or reliance upon the information furnished by the
Disclosing Party, as evidenced by documentary evidence to that effect or other competent proof.

The above exceptions will not apply to (i) any individual parts of the Confidential Information
merely because such parts are included in more general information, or (ii) any specific
combination of the items found in the Confidential Information merely because such combination can
be pieced together from multiple sources, none of which shows the whole combination.

     “Convicted” means (i) when a judgment or conviction has been entered by a federal or
state court in the Territory, regardless of whether there is an appeal pending; (ii) when a plea of
guilty or nolo contendere has been accepted by a federal or state court in the Territory; or (iii)
when a party has entered into participation in a first offender, deferred adjudication or other
similar arrangement or program where a judgment of conviction in a federal or state court in the
Territory has been withheld.

     “CPA Firm” has the meaning set forth in Section 4.2.1.

     “DEA” means the United States Drug Enforcement Administration, or any successor agency
with responsibilities comparable to those of the United States Drug Enforcement Administration.

     “Disclosing Party” has the meaning set forth in the definition of Confidential
Information.

     “Distributor” has the meaning set forth in the first paragraph of this Agreement.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

3

 

     “Distributor’s ANDA” means ANDA No. 78-506, along with all amendments and supplements
thereto.

     “Distributor Election” has the meaning set forth in the definition of Effective Date.

     “Distributor Indemnitees” has the meaning set forth in Section 8.1.

     “Effective Date” means the first to occur of (a) Purdue’s election to commence this
Agreement (the “Purdue Election”); and (b) Distributor’s election to commence this
Agreement (the “Distributor Election”), in either case, as of the date of such election at
any time after ***;
provided, however, that neither Party may make such election if (x) FDA
Approval has been granted on the same day or prior to either Party’s making such election or (y)
neither Party has made such election prior to ***.

     “Equivalent Supply Amount” has the meaning set forth in Section 2.1.7.

     “FDA” means the United States Food and Drug Administration, or any successor agency
with responsibilities comparable to those of the United States Food and Drug Administration.

     “FDA Approval” means the final approval by the FDA of Distributor’s ANDA to market
certain generic versions of controlled-release oxycodone products as described therein in the
Territory.

     “Final Cost of Goods Sold Payment” means payment of Purdue’s cost of goods sold for
the Remainder Supply Amount as set forth on Schedule 1.1B.

     “Final
Net Sales Payment” means ***% of aggregate Net Sales with respect to the
Remainder Supply Amount; provided, however, that to the extent any portion of the Remainder Supply
Amount has not been sold as of the date such payment is due, the Final Net Sales Payment will be
based on a good faith estimate of the Net Sales for such unsold portion.

     “Force Majeure Event” has the meaning set forth in Section 12.1.

     “GAAP” means United States generally accepted accounting principles, consistently
applied.

     “Good Manufacturing Practices” means current good manufacturing practices (i)
requirements of the FDA and other appropriate agencies, as set forth in 21 C.F.R. Parts 210 and
211, as amended from time to time, and (ii) set forth in all other Laws applicable to the
manufacture of the Products that are in effect at the time and place of manufacture of the
Products.

     “Governmental Authority” means within the Territory any (i) federal, state or local
government; (ii) court, arbitral or other tribunal or governmental or quasi governmental authority
of any nature (including any governmental agency, political subdivision, instrumentality, branch,
department, official, or entity); or (iii) body exercising, or entitled to exercise, any
administrative,

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

4

 

executive, judicial, legislative, police, regulatory, or taxing authority or power
of any nature pertaining to government.

     “Indemnifying Party” has the meaning set forth in Section 8.3.1.

     “Indemnitee” has the meaning set forth in Section 8.3.1.

     “Indemnitee Settlement” has the meaning set forth in Section 8.3.3.

     “Initial Cost of Goods Sold Payment” means payment of Purdue’s cost of goods sold for
the Initial Supply Amount as set forth on Schedule 1.1B.

     “Initial
Net Sales Payment” means ***% of aggregate Net Sales with respect to the
Initial Supply Amount; provided, however, to the extent any portion of the Initial Supply Amount
has not been sold as of the date such payment is due, the Initial Net Sales Payment will be based
on a good faith estimate of the Net Sales for such unsold portion.

     “Initial Supply Amount” means *** Bottles in the Product mix set forth on Schedule
3.1.1.

     “Inventoried Remaining Product” has the meaning set forth in Section 4.5.1.

     “Involuntary Recall” has the meaning set forth in Section 9.2.2.

     “Label” means any label, labeling, package inserts and packaging designed for use with
a Product.

     “Laws” means all applicable laws, rules, regulations, judgments, orders, subpoenas,
decrees, statutes, ordinances and other requirements of any Governmental Authority or
instrumentality within the Territory.

     “Losses” has the meaning set forth in Section 8.1.

     “Monthly Report” has the meaning set forth in Section 4.2.1.

     “NDA” means Purdue’s FDA New Drug Application number 20-553 (including all amendments
and supplements to the application).

     “NDC” means National Drug Code number.

     “Net Sales” means the gross amount invoiced for sale or other disposition of the
Products by Distributor and its Affiliates to Third Parties, less the following amounts directly
attributable to the Products: (a) sales and excise taxes, value added taxes, and duties which fall
due as a direct consequence of such sales and any other governmental charges imposed upon the
importation, use or sale, but only to the extent that such taxes and duties are (i) actually
included and itemized in the gross amounts invoiced to and specifically paid by the purchaser over
and above the usual selling price, (ii) not recovered or recoverable, and (iii) not income or
franchise taxes or taxes in lieu

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

5

 

thereof; (b) trade, sales, trade show, quantity and early payment
discounts and stocking allowances, except to the extent such discounts are greater than they
otherwise would be for similar products sold in similar competitive markets in order to gain,
maintain or otherwise facilitate sales of any of Distributor’s or its Affiliates’ other products;
(c) credits to customers for purchaser returns, returned goods allowances, billing and shipping
errors, recalls, rejected goods and damaged goods; (d) price adjustments, including those on
customer inventories following price changes; (e) allowances or credits to customers on account of
rejection, withdrawal, recall, or return; and (f) rebates, PBM administrative fees and wholesaler
chargebacks or similar credits or payments granted to customers pursuant to contract or otherwise,
including those granted to government agencies.

     “Net Sales Payment Certificate” has the meaning set forth in Section 4.2.1.

     “Party” means Purdue or Distributor and, when used in the plural, means Purdue and
Distributor.

     “Person” means any individual, group, corporation, partnership, joint venture, limited
liability company, trust, business association, organization, Governmental Authority, a division or
operating group of any of the foregoing or other entity or organization, including any successors
or assigns (by merger or otherwise) of any such entity.

     “Product” means, except when used in “Branded Products”, any of the authorized generic
versions of the Branded Products listed on Schedule 1.1C. Each NDC (dosage strength)
listed on Schedule 1.1C will constitute a separate Product. If the Purdue Election is made
and the Third Party Agreement is entered into, “Product” shall mean an AB rated generic version of
the Branded Product authorized for distribution and sale pursuant to the Third Party’s ANDA as set
forth in Section 2.1.7.

     “Purdue” has the meaning set forth in the first paragraph of this Agreement.

     “Purdue Election” has the meaning set forth in the definition of Effective Date.

     “Purdue Indemnitees” has the meaning set forth in Section 8.2.

     “Quality Agreement” means the Quality Agreement to be mutually agreed between the
Parties within 90 days after the date hereof.

     “Receiving Party” has the meaning set forth in the definition of Confidential
Information.

     “Remainder Supply Amount” means *** Bottles in the Product mix set forth on Schedule
3.1.1.

     “Risk Management Program” means the activities and security controls that Purdue will
require Distributor to follow as set forth on Schedule 1.1D, as may be amended by Purdue
from time to time, in its sole discretion.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

6

 

     “Selling Period” means the period beginning at 12:01 a.m., New York City time, on the
Effective Date and ending on the Selling Termination Date.

     “Selling Termination Date” means the earlier of (a) the date on which Distributor has
sold the entire Supply Amount and (b) ***.

     “Settlement Agreement” means the Settlement Agreement, dated as of the date hereof, by
and among Purdue (on its own behalf and as successor in interest to The Purdue Pharma Company, a
Delaware general partnership), The P.F. Laboratories, Inc., a New Jersey corporation and Purdue
Pharmaceuticals L.P., a Delaware limited partnership, and Distributor and its Affiliates.

     “Specifications” means, for a Product, such specifications (other than indicia and
name) for such Product as set forth in the NDA, as the same may be amended from time to time after
the date of this Agreement.

     “Supply Amount” means *** Bottles in the Product mix set forth on Schedule
3.1.1. For the avoidance of doubt, the Supply Amount means the maximum number of Bottles in
the Product mix set forth on Schedule 3.1.1 permitted to be sold hereunder and all sales
and the arrangement of sales of the Product must immediately cease no later than the Selling
Termination Date regardless of whether the amount of Bottles actually sold during the Selling
Period is less than the Supply Amount.

     “Term” has the meaning set forth in Section 11.1.

     “Territory” means the United States of America, its territories and possessions.

     “Third Party” means any Person who or which is neither a Party nor an Affiliate of a
Party.

     “Third Party Agreement” has the meaning set forth in Section 2.1.7.

     “Third Party Claim” has the meaning set forth in Section 8.1.

     “Trade” means wholesalers, chains, distributors, retailers, pharmacies, mail order
pharmacies or any other classes of trade that participate in the distribution or sale of
pharmaceutical products.

     “Voluntary Recall” has the meaning set forth in Section 9.2.1.

     1.2 Interpretations.

          1.2.1 In the event an ambiguity or a question of intent or interpretation arises, this
Agreement will be construed as if drafted jointly by the Parties and no presumption or burden of
proof will arise favoring or disfavoring any Party by virtue of the authorship of any provision of
this Agreement.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

7

 

          1.2.2 The definitions of the terms herein apply equally to the singular and plural forms of
the terms defined. Whenever the context may require, any pronoun will include the corresponding
masculine, feminine and neuter forms. The words “include”, “includes” and “including” will be
deemed to be followed by the phrase “without limitation.” Unless the context requires otherwise,
(A) any definition of or reference to any agreement, instrument or other document herein will be
construed as referring to such agreement, instrument or other document as from time to time
amended, supplemented or otherwise modified (subject to any restrictions on such amendments,
supplements or modifications set forth herein or therein), (B) any reference to any Laws herein
will be construed as referring to such Laws as from time to time enacted, repealed or amended, (C)
any reference herein to any Person will be construed to include the Person’s successors and
assigns, (D) the words “herein”, “hereof” and “hereunder”, and words of similar import, will be
construed to refer to this Agreement in its entirety and not to any particular provision hereof,
(E) any reference herein to the words “mutually agree” or “mutual written agreement” will not
impose any obligation on either Party to agree to any terms relating thereto or to engage in
discussions relating to such terms except as such Party may determine in such Party’s sole
discretion, and (F) all references herein without a reference to any other agreement to Articles,
Sections, Exhibits or Schedules will be construed to refer to Articles, Sections, Exhibits and
Schedules of this Agreement.

ARTICLE II

DISTRIBUTORSHIP/APPOINTMENT

     2.1 Appointment/Authorization.

          2.1.1 At any time after ***, but prior to ***, either Purdue or Distributor may cause this
Agreement to commence as of the Effective Date by making the Purdue Election or the Distributor
Election. The Effective Date of this Agreement shall only occur as a result of either the Purdue
Election or the Distributor Election. This Agreement shall automatically terminate and shall be of
no further force and effect if (a) FDA Approval is granted before either Party has made an election
to commence this Agreement or (b) neither Party has made such election prior to ***. If FDA
Approval were to be granted on the same day as either Party attempted to make an election, such FDA
Approval shall be deemed to have occurred prior to such attempted election and such attempted
election shall be null and void. Subject to the terms and conditions set forth in this Agreement
including those set forth in Section 2.1.7 below, upon and as of the Effective Date, Purdue
appoints Distributor as an authorized non-exclusive distributor of the Products not to exceed the
Supply Amount in the Territory during the Selling Period, and in connection with such appointment,
grants to Distributor the right to market, distribute and sell the Products in amounts not to
exceed the Supply Amount in the Territory during the Selling Period.

          2.1.2 Subject to the terms and conditions set forth in this Agreement including those set
forth in Section 2.1.7 below, Distributor accepts the appointment as an authorized distributor of
Products in the Territory from and after the Effective Date as provided in Section 2.1.1.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

8

 

          2.1.3 Pursuant to 21 C.F.R. §314.94(a)(12)(viii)(A), within *** days after receipt of the
Initial Supply Amount or the Equivalent Supply Amount if Purdue has made the election for
Distributor to enter into a distribution and supply agreement with a Third Party as set forth in
Section 2.1.7, Distributor shall submit to the FDA with a copy to Purdue, an amendment to the
patent certifications in Distributor’s ANDA with respect to the ’042 Patent, changing those
certifications to certifications under 21 C.F.R. §314.94(a)(12)(i)(A)(3) and unconditionally
requesting that the FDA promptly change the requested approval of the ANDA to a tentative approval
and, if Distributor’s ANDA has received effective approval, such approval be rescinded and instead
a tentative approval granted.

          2.1.4 [Intentionally left blank].

          2.1.5 Purdue specifically reserves the right, at its sole discretion, either directly or
through its Affiliates or Third Parties, to: (i) manufacture, distribute and sell the Products to
Distributor pursuant to this Agreement; and (ii) develop, manufacture, market, distribute and sell
any products (including the Products and the Branded Products) anywhere in the world, including in
the Territory.

          2.1.6 No rights, titles, interests, licenses, waivers, releases, authorizations or covenants
(either express or implied) other than those expressly granted in this Section 2.1 have been or are
granted (or should be construed to be granted) by or under this Agreement to Distributor in respect
of the NDA or any other intellectual property or drug applications owned or
controlled by Purdue or any of its Affiliates or with respect to the Products or the Branded
Products.

          2.1.7 In lieu of and in full satisfaction of its obligations under this Agreement to supply
the Supply Amount of Product to Distributor upon the making by Purdue of the Purdue Election or by
the Distributor of the Distributor Election, Purdue may elect for Distributor to enter into a
distribution and supply agreement with a Third Party (a “Third Party Agreement”), whereby
Distributor would be supplied by such Third Party with an amount of an AB rated generic version of
the Branded Product authorized for distribution and sale pursuant to the Third Party’s ANDA equal
to the Supply Amount of the Product (the “Equivalent Supply Amount”) at Purdue’s direction
and at the same cost that Purdue would sell Product to Distributor. If Purdue elects to have a
Third Party supply the Equivalent Supply Amount, (i) the provisions of this Agreement (including
the obligation of Distributor to withdraw its request for FDA Approval pursuant to Section 2.1.3),
to the extent applicable, shall remain in full force and effect, (ii) Distributor will use its
Commercially Reasonable Efforts to negotiate a Third Party Agreement with the Third Party in form
and substance similar to this Agreement and (iii) Purdue and Distributor will amend this Agreement
only to such extent as is necessary to reflect that such Third Party is supplying the Equivalent
Supply Amount instead of Purdue. Purdue shall provide Distributor with written notice of its
election under this Section 2.1.7 no later than three (3) Business Days after the making of the
Purdue Election or the Distributor Election, as the case may be. Failure of Purdue to provide such
written notice in a timely manner shall be deemed a waiver by it of its right to require
Distributor to enter into the Third Party Agreement. If, despite the use of its Commercially

 
 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

9

 

Reasonable Efforts, Distributor is unsuccessful in negotiating and entering into a Third Party
Agreement within thirty (30) days of the commencement of such negotiations with the Third Party
following a Purdue Election, Distributor shall not be required to enter into a Third Party
Agreement and the provisions of this Agreement shall remain in full force and effect. For clarity
and notwithstanding anything in this Agreement to the contrary, (i) Purdue shall remain fully
liable to Distributor for such Third Party’s performance of Purdue’s obligations to Distributor
under this Agreement and (ii) Purdue’s indemnification obligations under Section 8.1 shall include
any Third Party claims arising from or in connection with such Third Party’s gross negligence or
willful misconduct or breach of any of Purdue’s representations, warranties, covenants or
agreements under this Agreement.

          2.1.8 Purdue hereby covenants that neither it, nor any of its Affiliates, will sue, assert any
claim or counterclaim against or otherwise participate in any action or proceeding in the United
States against Distributor, its Affiliates or purchasers of Product claiming that the sale or offer
for sale of Product pursuant to this Agreement infringes any patents owned, licensed or controlled
by the Purdue Companies or their Affiliates now or in the future. This covenant not to sue shall
be non-transferable (except as provided in Section 12.3 of this Agreement). Nothing in this
Section 2.1.8 shall be interpreted to prohibit Purdue or its Affiliates from suing, asserting any
claim or counterclaim against or otherwise participating in any action or proceeding against
Distributor or its Affiliates not specifically precluded by this Section 2.1.8, including in order
to enforce this Agreement, the Settlement Agreement or the Consent Judgment (as such term is
defined in the Settlement Agreement).

     2.2 Limitation on Rights.

          2.2.1 Distributor is, and will remain subject at all times prior to, during and following the
Term, to the terms and conditions of the Settlement Agreement.

          2.2.2 Distributor hereby acknowledges Purdue’s ownership of the NDA. Pursuant to the
Settlement Agreement and the terms of this Agreement, Distributor will not (i) directly or
indirectly contest the validity of the NDA or the right and title of Purdue therein and thereto, or
(ii) claim or represent that under this Agreement Distributor has acquired any title in, ownership
of, or right of reference to, the NDA or any other Purdue intellectual property or new drug
application.

          2.2.3 Distributor will not use the NDA in any way other than in accordance with this
Agreement.

          2.2.4 Except pursuant to the terms of the Settlement Agreement and this Agreement, Distributor
will not, directly or indirectly through its Affiliates or Third Parties solicit offers for sale,
offer to sell, sell, ship, or cause to be shipped into interstate commerce for commercial sale in
the Territory, or make, have made, import, develop, acquire, license, distribute, promote or market
in the Territory, any AB rated generic version of any Branded Product. During the Term, in no
event will Distributor submit an ANDA to the FDA or any other Governmental

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

10

 

Authority for any AB rated generic version of any Branded Product, except that Distributor may maintain on file, as
provided for in the Settlement Agreement, Distributor’s ANDA.

          2.2.5 Without the prior written consent of Purdue, which may be withheld in Purdue’s sole
discretion, Distributor will not grant sub-Distributorships or otherwise assign or grant an
interest in any of its rights or obligations under this Agreement, in whole or in part, to its
Affiliates or to Third Parties.

     2.3 Distributor Obligations.

          2.3.1 Commencing on the Effective Date, Distributor will use Commercially Reasonable Efforts
to market, sell and distribute and will be responsible for marketing, sales and distribution of,
the Products to the Trade throughout the Territory, including all operations relating to any of the
foregoing (including pricing, invoicing, collections, customer returns, contracting, and rebates,
including Medicaid rebates), and Distributor will comply with all Laws relating to all of the
foregoing.

          2.3.2 In order to ensure proper allocation of Net Sales to Purdue, unless otherwise permitted
in writing by Purdue in advance, Distributor shall not sell Products as part of (i) a Bundled
Product or (ii) in any discounting program in which Distributor’s terms and conditions for sale are
not applied to the Products in the same way that they are applied to the majority of Distributor’s
other products. If no written permission is given by Purdue in advance and a Product is part of
such a Bundled Product or such a discounting program, then the Product sale will be treated for
purposes of this Agreement as if it were made at Distributor’s then prevailing list price for such
Product.

          2.3.3 Distributor will market, sell and distribute all Products with the approved Label
pursuant to Section 3.1.4.

     2.4 Meetings. The Parties will meet as needed, at such times and locations as are
mutually acceptable to the Parties, to discuss each Party’s obligations under this Agreement and
any disputes relating to the performance by each Party of its obligations hereunder. In connection
with the foregoing, each Party will be responsible for all travel and related costs and expenses
for its attendees at all such meetings in accordance with this Section 2.4.

ARTICLE III

GENERAL TERMS OF SUPPLY

     3.1 Sales and Supply of Product.

          3.1.1 Subject to the provisions of Section 2.1.7, if the Effective Date occurs, subject to
Distributor’s compliance with Section 3.1.4 with respect to the selection of the indicia and Label,
Purdue will use its best efforts to complete shipping to Distributor, no later than *** days after
the Effective Date (but in no event later than *** days after the Effective Date), the

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

11

 

Initial Supply Amount in the Product mix set forth on Schedule 3.1.1 subject to receiving from Distributor
all documentation required by this Agreement or any Laws, including DEA Form 222. If Distributor
makes the payments with respect to the Initial Supply Amount required by Section 4.1 within the
time period set forth therein, Purdue will complete shipping to Distributor, no later than *** days
after the date it receives the payments described above, the Remainder Supply Amount in the Product
mix set forth on Schedule 3.1.1, subject to receiving from Distributor all documentation required
by this Agreement or any Laws, including DEA Form 222. If Distributor does not make the payments
required by Section 4.1 within the time period set forth therein, Purdue may elect, at its sole
discretion, to terminate Distributor’s right to receive the Remainder Supply Amount. If Purdue
elects to so terminate Distributor’s right, it shall send Distributor notice of such election.
Purdue’s exercise of such election shall have no effect on any other rights or obligations of the
Parties hereunder, including Distributor’s obligation to make the Initial Cost of Goods Sold
Payment and the Initial Net Sales Payment.

          3.1.2 Distributor will sell the Products in accordance with the terms of this Agreement and
immediately cease selling, marketing, and distributing the Products at the conclusion of the
Selling Period.

          3.1.3 All Products supplied hereunder will be in finished dosage form, filled, packaged and
Labeled for commercial sale in accordance with the terms and conditions of this Agreement, the
Quality Agreement, the Specifications and applicable Laws. Purdue will be responsible for the
purchase of all materials that are included in finished Products. If due to limitations on
Purdue’s receiving a sufficient DEA quota of oxycodone or other materials, Purdue does not have
sufficient manufacturing capacity to fulfill Distributor’s scheduled requirements for the Product
in accordance with Section 3.1.1, Purdue may elect to extend the Selling Termination Date for up to
*** months to enable it to supply such Product.

          3.1.4 Distributor will use the indicia selected by Purdue and will agree with Purdue within 30
days of the date hereof on a Label. Nothing contained herein will prevent Purdue
from modifying the indicia or Labeling, so long as such changes conform to FDA requirements
and the NDA relating to the Products. Purdue will be responsible for all indicia and Label
modification costs if Purdue initiates any modification or change in the indicia or Label, or if
the FDA requires the indicia or Label to be modified or changed. Purdue will notify Distributor
promptly following a final decision to make changes to the indicia or Label or, if FDA approval is
required, to seek approval for such changes, but in no event will Distributor be given less than 30
calendar days’ advance written notice of such modification, unless a shorter time is required to
comply with FDA requirements. If Purdue elects to have a Third Party supply the Supply Amount,
Distributor, Purdue and the Third Party will agree on the Label within 30 days after Purdue gives
Distributor notice of such election under Section 2.1.7.

     3.2 Shipment.

          3.2.1 With KV’s consent, which will not be unreasonably withheld, conditioned or delayed, the
Supply Amount may be adjusted among dosage strengths, without altering the total

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

12

 

API contained in the Supply Amount, to be in quantities consistent with Purdue’s then current minimum validated
batch sizes for such Product, or multiples thereof.

          3.2.2 No terms and conditions contained in any preprinted form issued by either Party will be
effective to the extent they are inconsistent with or modify the terms and conditions contained
herein or in either the Quality Agreement or the Settlement Agreement.

     3.3 Storage and Shipments.

          3.3.1 Purdue will store and transport Products, and other Product materials and API according
to the Specifications for the Products and applicable Good Manufacturing Practices.

          3.3.2 Purdue will notify Distributor when the scheduled delivery amounts become available for
shipment. Within twenty-four (24) hours after receiving such notice, Distributor will provide to
Purdue a DEA Form 222 and mutually agree with Purdue on a shipment date for the scheduled delivery
amounts.

          3.3.3 Within two Business Days after the mutually agreed upon shipment date pursuant to
Section 3.3.2, and Purdue’s receipt of all required documentation, including DEA Form 222, Purdue
will ship Product to Distributor’s designated distribution facility listed on Schedule
3.3.3 (which may be amended by written agreement of the Parties from time to time) on Purdue’s
customary carrier, C.I.P. (Incoterms 2000) customer destination, except that no shipments will be
made on Friday, Saturday, Sunday, a legal holiday, or the day before a legal holiday in any week,
and shipments due for those days will commence on the following Business Day.

          3.3.4 Each Party will be responsible for its own DEA reporting, where applicable. Purdue will
obtain and pay for freight insurance, custom clearance (if necessary), and any duties or taxes in
connection with the shipment of any Product to Distributor’s designated distribution facility.
Only following approval and release from Purdue’s quality assurance group will Product be shipped
to Distributor.

          3.3.5 Purdue will package the Product for shipment in accordance with its customary practices.
Purdue will include the following with its shipment of the scheduled delivery amounts: (a) the
Purdue lot and batch numbers for the Products constituting such scheduled delivery amounts, (b) the
quantity of the Products included, (c) the Certificate of Analysis and (d) the Certificate of
Compliance.

     3.4 Product Rejection.

          3.4.1 Distributor will give written notice to Purdue of any claim that any Product does not
conform with the requirements set forth in the Quality Agreement promptly upon Distributor becoming
aware of such non-compliance, but in no event later than seven calendar days after receipt of such
Product by Distributor. In the event that Distributor fails to notify

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

13

 

Purdue of any such claim
within the applicable notice period specified in the preceding sentence, such Product will be
deemed accepted by Distributor. Any such notice by Distributor pursuant to this Section 3.4.1 that
any Product does not conform with the requirements set forth in the Quality Agreement must be
accompanied by a reasonably detailed statement of Distributor’s findings of non-conformance. Such
non-compliance is limited to physical inspection of the finished goods, as the Parties do not
intend any method transfer protocol to be set forth herein. The Parties will cooperate in good
faith to resolve any dispute arising under this Section 3.4.1. Distributor will not dispose of any
Product claimed by it not to conform with the terms and conditions hereof until resolution of any
dispute with respect thereto is finalized by the Parties. Such resolution may include a mutually
agreed upon method to replace or re-label the non-conforming materials.

          3.4.2 If Purdue acknowledges an alleged nonconformity in writing, Purdue will promptly (and in
any case within 10 Business Days thereafter) make arrangements for the return or disposal, at
Purdue’s option, of the non-conforming Product, if in fact, the non-conforming Product cannot be
reworked. Non-conformance relating to physical labeling or packaging will be addressed first by
reworking the Product into acceptable physical labeling and/or packaging. If Purdue instructs
Distributor to dispose of such non-conforming Product, Purdue will give Distributor written
instructions as to the process by which Distributor or its agent must dispose of such
non-conforming Product, and Distributor will provide Purdue with written certification of such
destruction. Purdue will have the right to witness such destruction. Purdue will be under no
obligation to accept a return of Product except as provided in this Section 3.4.2.

          3.4.3 If Product was in fact non-conforming (whether pursuant to Section 3.4.1 or if Purdue so
acknowledges in writing), then, Purdue will use Commercially Reasonable Efforts to provide
replacement Products for such non-conforming Product if Distributor returns such Product to Purdue
or destroys such Product as instructed by Purdue. Replacement shipments will also be subject to
the Product rejection procedures contained in this Section 3.4. The Selling Period will be
extended for a period equal to the time elapsed between the original scheduled delivery date of
Product and the receipt of replacement Product.

     3.5 Quality Control; Change in Specifications.

          3.5.1 The quality control obligations with respect to the manufacture, handling, storage and
shipment of the Products are set forth in the Quality Agreement.

          3.5.2 All changes to Specifications must be in accordance with Purdue’s change control
procedure set forth in the Quality Agreement.

ARTICLE IV

PAYMENTS AND REPORTS

     4.1 Payment to Purdue. As consideration to Purdue for the rights granted to
Distributor under this Agreement, Distributor will, in accordance with the terms of this Article
IV, pay to Purdue (i) the Initial Cost of Goods Sold Payment and the Initial Net Sales Payment
within 45

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

14

 

calendar days of the delivery of the Initial Supply Amount pursuant to Section 3.1 of
this Agreement and (ii) the Final Cost of Goods Sold Payment and the Final Net Sales Payment within
30 calendar days after the last sale of Products made under this Agreement. The calculation of Net
Sales shall be made in accordance with the definition thereof and in accordance with GAAP.
Simultaneously with the delivery of the Initial Supply Amount and the Remainder Supply Amount,
Purdue shall deliver to Distributor a certificate from the Executive Vice President, Chief
Financial Officer of Purdue certifying the amount of the Initial Cost of Goods Sold Payment for the
Initial Supply Amount or the Final Cost of Goods Sold Payment for the Remainder Supply Amount, as
the case may be, calculated in accordance with Schedule 1.1B.

     4.2 Reporting Obligations and Audit Rights.

          4.2.1 Each of the Initial Net Sales Payment and the Final Net Sales Payment by Distributor
hereunder shall be accompanied by a certificate (the “Net Sales Payment Certificate”) from
the Chief Financial Officer of Distributor or other executive officer of Distributor certifying as
to (i) the number of Bottles of Products in each dosage strength sold by Distributor, (ii) the Net
Sales derived from the sale of such Bottles, and (iii) the amount of the Net Sales payments payable
with respect to such Net Sales. The Net Sales Payment Certificate will specify the extent to which
the applicable Net Sales payment is based upon a good faith estimate of the Net Sales for any
unsold portion of the Initial Supply Amount or Remainder Supply Amount, as the case may be. If
Purdue disputes either of the Net Sales Payment amounts set forth in the Net Sales Payment
Certificate, such dispute shall be resolved in accordance with this Section 4.2.1. In addition,
Distributor shall deliver a report to Purdue for each calendar month during the Term that
summarizes the following: (i) the total number of Bottles shipped, on a dosage strength by dosage
strength basis, for such month; (ii) the number of returns, on a dosage strength by dosage strength
basis, during such month; (iii) the differences between the number of Bottles shipped and returns
for each month, on a dosage strength by dosage strength basis; (iv) the total number of Bottles
shipped, on a dosage strength by dosage strength basis, since the Effective Date; (v) the number of
returns, on a dosage strength by dosage strength basis since the Effective Date; and (vi) the
difference between (iv) and (v), on a dosage strength by dosage strength basis (each a “Monthly
Report”). Distributor shall deliver each Monthly Report to Purdue no later than five (5)
calendar days after the end of the month that such Monthly Report covers to the attention of:
Executive Vice President, Chief Financial Officer of Purdue, One Stamford Forum, 201 Tresser
Boulevard, Stamford, CT 06901-3431.

                    (a) Purdue shall have the right to engage Deloitte & Touche Financial Advisory Services LLP,
or another independent certified public accounting firm chosen by Purdue
and reasonably acceptable to Distributor (a “CPA Firm”), to conduct an audit of
Distributor for the purposes of confirming compliance with this Agreement, including the amount of
Net Sales and the Initial Net Sales Payment and the Final Net Sales Payment. Such right shall
exist during the Term and for a period of two (2) years after the Term and shall be limited to
conducting such an audit no more than once per calendar year.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

15

 

                    (b) The CPA Firm shall be given access to and shall be permitted to examine and copy such
books and records of Distributor as it shall request upon ten (10) Business Days’ notice having
been given by Purdue, during regular business hours, for the purpose of determining compliance with
this Agreement, including the amount of Net Sales and the Initial Net Sales Payment and the Final
Net Sales Payment. Prior to any such examination taking place, the CPA Firm shall enter into a
confidentiality agreement reasonably acceptable to Distributor with respect to the information to
which it is given access.

                    (c) If the CPA Firm determines non-compliance with this Agreement, including that the amount
of Net Sales or the Initial Net Sales Payment or the Final Net Sales Payment is incorrect, then
Purdue and Distributor shall be entitled to receive a full written report of the CPA Firm with
respect to its findings. The determination by the CPA Firm following such audit shall be final and
binding on the Parties, unless Distributor or Purdue challenges the findings of the CPA Firm. In
the event Distributor or Purdue challenges the findings of the CPA Firm, the Parties shall submit
such findings to a binding arbitrator, mutually acceptable to both Parties, and the findings of
such arbitrator shall be binding upon the Parties.

                    (d) Upon completion of the CPA Firm’s audit, Distributor shall pay to Purdue the Initial Net
Sales Payment amount or the Final Net Sales Payment amount that remains unpaid as determined by the
CPA Firm. If the report of the CPA Firm shows that the Initial Net Sales Payment or the Final Net
Sales Payment to which Purdue is entitled differs from the Net Sales amount reflected by
Distributor in the Net Sales Payment Certificate, then in addition to the payment of the Initial
Net Sales Payment or the Final Net Sales Payment amount that remains unpaid, Distributor shall be
responsible for late payment interest from the date that the payment would have been due to Purdue
and, if such difference is greater than ***%, for the fees and expenses of the CPA Firm in
performing such audit. If the report of the CPA Firm shows a
difference of less than ***%, each
Party shall pay one-half of the fees and expenses of the CPA Firm in performing such audit. If the
CPA Firm confirms that the Initial Net Sales Payment or the Final Net Sales Payment, as the case
may be, reflected by Distributor in the Net Sales Payment Certificate is correct, Purdue shall be
responsible for the fees and expenses of the CPA Firm in performing such audit. Distributor shall
cooperate with the CPA Firm in conducting such audit, including by providing sales records relating
to Distributor’s sale of Products.

     4.3 Mode of Payment. Distributor will make all payments required under this Agreement
by electronic funds wire transfer in United States dollars to a bank account designated by Purdue
from time to time. Distributor will give Purdue one Business Day’s written notice prior to making
any such wire transfers.

     4.4 Records Retention. Distributor will keep complete, true and accurate records
pertaining to its activities under this Agreement, including records pertaining to the sales of
Products in the Territory and covering all transactions from which Net Sales are derived, in
accordance with and for the time period required by Law, but in no event for a period of less
than ten calendar years after the year in which such sales occurred (as currently required by Law),
and in sufficient detail to permit Purdue to confirm the accuracy of Net Sales, the Initial Net
Sales

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

16

 

Payment and the Final Net Sales Payment due under this Agreement, the applicable “average
manufacturer price” and/or the applicable “best price”.

     4.5 Certificates; Audit.

          4.5.1 Immediately upon the conclusion of the Selling Period, Distributor will give Purdue
access to Distributor’s facilities, or such other places that Product is stored, upon reasonable
notice in advance, in order to inventory the remaining Product (the “Inventoried Remaining
Product”). Following the conclusion of the Selling Period, Distributor will also deliver to
Purdue certificates from the Chief Executive Officer or the Chief Financial Officer of Distributor
certifying (i) that Distributor ceased shipping the Product into interstate commerce for commercial
sale in the Territory on the Selling Termination Date, (ii) the number of Bottles, allocated by
dosage strength, sold by Distributor during the Selling Period, (iii) that all Inventoried
Remaining Product has been or will be destroyed or returned to Purdue at Distributor’s sole cost
and expense within five Business Days following the Selling Termination Date and (iv) that no sales
resulting in sales above the Supply Amount were made by Distributor prior to the Selling
Termination Date. The certifications referred to in clause (i) above will be delivered within two
(2) Business Days following the Selling Termination Date and the certifications referred to in
clauses (ii)-(iv) above will be delivered within ten (10) calendar days following the Selling
Termination Date.

          4.5.2 Purdue will have the right to engage the CPA Firm to conduct an audit of Distributor for
the purpose of confirming that no sales of any AB rated generic version of the Branded Product or
Product by Distributor occurred other than during the Selling Period. Subject to its entering into
a confidentiality agreement reasonably acceptable to Distributor, the CPA Firm will be given access
to and will be permitted to examine and copy such books and records of Distributor as it will
reasonably request upon five Business Days’ prior written notice having been given by Purdue for
the purpose of reporting to the Parties that no sales of any AB rated generic version of the
Branded Product or Product by Distributor occurred other than during the Selling Period. The
determination by the CPA Firm following such audit will be final and binding on the Parties.
Distributor will cooperate with and will cause its Affiliates to cooperate with all reasonable
requests of the CPA Firm in conducting such audit, including by providing sales records relating to
its sale of any Product.

     4.6 Taxes. Any and all transfer, sales, use, registration and other taxes imposed
upon or with respect to or measured by the shipment by Purdue to Distributor of any Product under
this Agreement will be the responsibility of and for the account of Distributor. Notwithstanding
the previous sentence, Distributor will have no obligation to pay any income tax imposed on Purdue
or any of its Affiliates which may arise from the transactions contemplated by this Agreement.

     4.7 Late Payments. In the event that any payment due by Distributor under this
Agreement is not made when due, the payment will accrue interest from the date due at a rate equal
to the lesser of (a) *** percent (*** %) above the prime rate reported in The Wall Street Journal (Eastern Edition)
on the date such payment was due but not less than *** percent (*** %) and (b) the maximum permissible rate

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

17

 

under Law, with such interest to compound monthly. The payment of such interest will not limit
Purdue from exercising any other rights it may have as a consequence of the lateness of any
payment.

     4.8 Notice of Destruction of Records. Notwithstanding any other provision of this
Agreement to the contrary, neither Party will destroy any records created under this Agreement
without first giving the other Party advance written notice so that such Party may request
additional retention of such records for good cause.

ARTICLE V

COVENANTS

     5.1 Mutual Covenants.

          5.1.1 Compliance with Laws. Each Party will maintain in full force and effect all
necessary licenses, permits and other authorizations required by Law to carry out its duties and
obligations under this Agreement. Each Party will comply in all material respects with all Laws
applicable to its activities under this Agreement and the Quality Agreement. Distributor and
Purdue will handle and store the Products in compliance in all material respects with all
applicable Laws. Each Party will keep all records and reports required to be kept by applicable
Laws. The Parties will reasonably cooperate with one another with the goal of ensuring full
compliance in all material respects with applicable Laws. Each Party will cooperate with the other
to provide such letters, documentation and other information on a timely basis as the other Party
may reasonably require to fulfill its reporting and other obligations under applicable Laws to
applicable Governmental Authorities.

          5.1.2 Reasonable Cooperation. Purdue and Distributor will each use Commercially
Reasonable Efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all
things necessary or proper to make effective the transactions contemplated by this Agreement,
including such actions as may be reasonably necessary to obtain any approvals and consents of
Governmental Authorities and other Persons; provided that no Party will be required to
assume any other material obligation not otherwise required to be assumed by this Agreement or the
Quality Agreement.

     5.2 Purdue Covenants.

                    (a) Purdue will comply in all material respects with all applicable Laws (including DEA and
FDA regulations) relating to the manufacturing, packaging, Labeling, handling, storage and shipment
of the Products, including filing with the FDA required notices, supplemental applications and
annual or other reports, including adverse event reports, with respect to the NDA, except to the
extent such non-compliance would not have a material adverse effect on the NDA, Branded Products or
Products.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

18

 

                    (b) Purdue will perform all stability and other testing sufficient to maintain the Product in
conformity with the NDA.

                    (c) The Products manufactured by Purdue and supplied to Distributor under this Agreement:

                    (i) will not be adulterated under applicable Laws at the time they are tendered to
Purdue’s customary carrier for shipment to Distributor;

                    (ii) will meet the Specifications therefor at the time they are tendered to Purdue’s
customary carrier for shipment to Distributor;

                    (iii) will be manufactured, packaged and Labeled in accordance with Good Manufacturing
Practices; and

                    (iv) will have a shelf life of not less than twenty (20) months at the time the
Products are tendered to Purdue’s customary carrier for shipment to Distributor.

                    (d) Labels of Products will not be misbranded under applicable Laws, will meet the
Specifications, and will be Labeled in accordance with Good Manufacturing Practices at the time the
Products are tendered to Purdue’s customary carrier for shipment to Distributor.

                    (e) Purdue will review all marketing and sales materials within 30 Business Days after receipt
from Distributor.

                    (f) Purdue will immediately inform Distributor if Purdue or any of its Affiliates providing
services to Distributor in connection with this Agreement are debarred, under Section 306(a) or
306(b) of the Generic Drug Enforcement Act of 1992 or under 42 U.S.C. Section 1320-7, or are
sanctioned by, suspended, excluded or otherwise ineligible to participate in any federal health
care program, including Medicare and Medicaid or in Federal procurement or non-procurement
programs.

     5.3 Distributor Covenants.

                    (a) Distributor will only sell and distribute the Product in the Territory, or make or solicit
offers to sell the Product in the Territory during the Selling Period and in no event will such
sales of the Product exceed the Supply Amount.

                    (b) Distributor will comply in all material respects with all applicable Laws (including DEA
and FDA regulations) relating to the handling, storage and disposal of the Products.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

19

 

                    (c) Distributor will comply with all applicable Laws related to the marketing, distribution
and sale of the Products.

                    (d) Prior to Distributor using any marketing and sales materials pursuant to this Agreement,
Distributor will submit to Purdue for Purdue’s written approval all such marketing and sales
materials.

                    (e) Distributor will be responsible for all pricing decisions with respect to the Products.

                    (f) In accordance with applicable Law, Distributor will register and sell the Products using
only NDC numbers that reflect Distributor as the distributor of the Products.

                    (g) Distributor will be responsible for all price reporting under Distributor’s own NDC for
the Products to any and all Governmental Authorities, as well as to any Third Party pricing
publications.

                    (h) Distributor will cause its employees responsible for the supply, distribution, sale or
marketing of the Products in the Territory to act in accordance with the highest standards of the
industry and in a professional, ethical and lawful manner, consistent with the same diligence used
with regard to other products marketed by Distributor.

                    (i) Distributor acknowledges that nothing in this Agreement will grant to Distributor any
rights, titles, interests, licenses, waivers, releases, authorizations or covenants to, or interest
in, either express or implied, any intellectual property improvements, new formulations,
indications, dosages, forms of administration, dosage strengths, or other presentations or uses of
Product at any time, whether past, present or future, derived or developed by or on behalf of
Purdue or its Affiliates, or any other product, compound or molecule owned or controlled, in whole
or in part, by Purdue or its Affiliates.

                    (j) Distributor will not market, distribute or sell the Product to any Third Party in the
Territory for resale outside of the Territory.

                    (k) Distributor will process and be responsible for all rebates, price protection claims and
payments to Medicaid, Medicare, PBMs (pharmacy benefit managers) and other payors under
Distributor’s NDC number, whether required by contract or Law, for the Products. Furthermore, for
all rebates due under or calculated under 42 U.S.C. 1396r-8, Distributor acknowledges that it will
treat the Products as innovator multiple source drugs, as defined in 42 U.S.C.
1396r-8(k)(7)(A)(ii), and that Distributor will carry over the base average manufacturer price for
the Products in accordance with HCFA Labeler Release No. 26.

                    (l) Distributor will timely provide Purdue with Medicare “best price” and “average
manufacturers price” data on a 9 and 11 digit NDC basis for each of the Products.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

20

 

                    (m) Distributor will take all reasonable actions to ensure that all discounts and price
reductions offered to its customers and included in the definition of Net Sales fall within the
discount safe-harbor to the federal anti-kickback statute, as described in 42 U.S.C.
1320a-7b(b)(3)(A) and 42 C.F.R. 1001.952(h).

                    (n) Distributor will process all customer returns of Product.

                    (o) Distributor will credit customers for the customers’ Product returns in accordance with
Distributor’s general returns policy that applies to all of Distributor’s products, including the
Products.

                    (p) Distributor will immediately inform Purdue if Distributor or any of its Affiliates
providing services to Purdue in connection with this Agreement are debarred, under Section 306(a)
or 306(b) of the Generic Drug Enforcement Act of 1992 or under 42 U.S.C. Section 1320-7, or are
sanctioned by, suspended, excluded or otherwise ineligible to participate in any federal health
care program, including Medicare and Medicaid or in Federal procurement or non-procurement
programs.

                    (q) Distributor will comply with the Risk Management Program. Upon Purdue amending the Risk
Management Program, Distributor will implement any additional risk management activities under such
amended Risk Management Program as soon as possible.

ARTICLE VI

REPRESENTATIONS AND WARRANTIES

     6.1 Representations and Warranties of Both Parties. Each of Purdue and Distributor
represents and warrants to the other Party that:

          6.1.1 Organization. Each Party is duly organized and validly existing under the laws
of its state of formation.

          6.1.2 Authority. Each Party has all the requisite power and authority to execute and
deliver this Agreement and the Quality Agreement and to perform all of its obligations hereunder
and thereunder. The execution and delivery of this Agreement and the Quality Agreement and the
performance by the Parties of their respective obligations hereunder and thereunder have been
authorized by all requisite limited partnership or corporate action, as applicable, on their
respective parts. This Agreement has been validly authorized, executed and delivered by each Party
and constitutes a valid and binding obligation of each Party, enforceable against each Party in
accordance with its terms.

          6.1.3 Consents and Approvals; No Violations.

                    (a) Except as otherwise set forth in this Agreement or the Settlement Agreement, no material
filing with, and no material permit, authorization, consent or approval of

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

21

 

any Governmental
Authority is necessary for the consummation by each Party of the transactions contemplated by this
Agreement and the Quality Agreement, except for those filings, permits, authorizations, consents or
approvals, the failure of which to be made or obtained would not materially impair such Party’s
ability to consummate the transactions contemplated hereby, or materially delay the consummation of
the transactions contemplated hereby.

                    (b) Neither the execution and delivery of this Agreement or the Quality Agreement by either
Party, nor the performance by such Party of its obligations hereunder or thereunder, will (i)
violate the organizational documents of such Party; or (ii) violate or conflict in any material
respect with any Law, rule, regulation, judgment, order or decree of any court or Governmental
Authority applicable to such Party or any Product, except for violations, breaches or defaults
which would not have a material adverse effect on such Party’s ability to consummate the
transactions contemplated hereby.

     6.2 Additional Purdue Representations and Warranties. Purdue represents and warrants to
Distributor that:

                    (a) Purdue or one of its Affiliates owns and possesses all right, title and interest in, to
and under the NDA.

                    (b) The NDA has been approved by the FDA, and neither Purdue nor any of its Affiliates has
received any notice in writing that has, or reasonably should have, led Purdue to believe that such
NDA is not currently effective or not currently in material compliance with all material Laws.

                    (c) Neither the execution and delivery of this Agreement nor the performance of Purdue’s
obligations hereunder will conflict in any material respect with or result in a material violation
or breach of, or constitute a material default under, any contract, agreement or instrument to
which Purdue is bound.

                    (d) None of Purdue nor any of its Affiliates providing services to Distributor in connection
with this Agreement has ever been:

                    (i) debarred, under Section 306(a) or 306(b) of the Generic Drug Enforcement Act of
1992, or under 42 U.S.C. Section 1320-7;

                    (ii) sanctioned by, suspended, excluded or otherwise ineligible to participate in any
federal health care program, including Medicare and Medicaid or in Federal procurement or
non-procurement programs; or

                    (iii) charged with or Convicted of any
felony or misdemeanor under 42 U.S.C. Section 1320a-7(a) or 42
U.S.C. Section 1320a-7(b)(1)-(3), or otherwise proposed for
exclusion.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

22

 

     6.3 Additional Distributor Representations and Warranties. Distributor represents and
warrants to Purdue that:

               (a) Distributor has utilized its own marketing and distribution expertise and experience to
analyze and evaluate the commercial value of the Product and has solely relied on such analysis and
evaluations in deciding to enter into this Agreement.

               (b) Neither Distributor nor any of its Affiliates is a party to or otherwise bound by any oral
or written contract or agreement that will result in any Person obtaining any interest in, or that
would give to any Person any right to assert any claim in or with respect to, any of Distributor’s
rights under this Agreement.

               (c) Neither the execution and delivery of this Agreement or the Quality Agreement nor the
performance of its obligations hereunder or thereunder will conflict in any material respect with
or result in a material violation or breach of, or constitute a material default under, any
contract, agreement or instrument to which Distributor is bound, or result in the creation or
imposition of any lien upon any Product.

               (d) None of Distributor nor any of its Affiliates providing services to Purdue in connection
with this Agreement has ever been:

               (i) debarred, under Section 306(a) or 306(b) of the Generic Drug Enforcement Act of
1992, or under 42 U.S.C. Section 1320-7;

               (ii) sanctioned by, suspended, excluded or otherwise ineligible to participate in any
federal health care program, including Medicare and Medicaid or in Federal procurement or
non-procurement programs; or

               (iii) charged with or Convicted of any felony or misdemeanor under 42 U.S.C. Section
1320a-7(a) or 42 U.S.C. Section 1320a-7(b)(1)-(3), or otherwise proposed for exclusion.

               (e) None of Distributor nor any of its Affiliates has made any offers for sales or customer
solicitations for any AB rated generic version of the Branded Product prior to the date of the
Settlement Agreement.

     6.4 No Reliance by Third Parties. The representations and warranties of each Party
set forth in this Agreement are intended for the sole and exclusive benefit of the other Party
hereto, and may not be relied upon by any Third Party.

     6.5 Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT OR THE
SETTLEMENT AGREEMENT, NEITHER PARTY NOR THEIR AFFILIATES MAKES ANY REPRESENTATIONS OR EXTENDS ANY
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE,

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

23

 

OR NON-INFRINGEMENT, INCLUDING (1) FOR PURDUE
WITH RESPECT TO PURDUE’S PATENTS, (2) ANY MATERIALS OR INFORMATION PROVIDED BY SUCH PARTY OR ANY OF
ITS AFFILIATES UNDER THIS AGREEMENT OR THE SETTLEMENT AGREEMENT, OR (3) WITH RESPECT TO ANY PRODUCTS OR SERVICES OF EITHER PARTY HERETO
OR THEIR AFFILIATES. FURTHERMORE, UNLESS EXPRESSLY STATED IN THIS AGREEMENT OR THE SETTLEMENT
AGREEMENT, NOTHING IN THIS AGREEMENT OR THE SETTLEMENT AGREEMENT SHALL BE CONSTRUED AS A WARRANTY
THAT ANY OF PURDUE’S PATENTS, THE PRACTICE OF ANY INVENTION CLAIMED IN ANY OF PURDUE’S PATENTS OR
OTHER PROPRIETARY RIGHTS INCLUDED IN ANY OF PURDUE’S PATENTS OR ANY RIGHTS GRANTED BY PURDUE DO
NOT, OR THE MAKING, HAVING MADE, USING, SELLING, OFFERING FOR SALE OR IMPORTING OF DISTRIBUTOR’S
PRODUCTS BY ANY PERSON DOES NOT, INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS
OF ANY THIRD PARTY. IT IS HEREBY AGREED AND ACKNOWLEDGED BY DISTRIBUTOR THAT PURDUE IS GIVING NO
GUARANTEE OR WARRANTY, EXPRESS OR IMPLIED, TO DISTRIBUTOR IN RELATION TO THE SAFETY OR THERAPEUTIC
EFFECTIVENESS OF THE DISTRIBUTOR’S PRODUCTS OR THE VALIDITY OR ENFORCEABILITY OF ANY INTELLECTUAL
PROPERTY RIGHTS. FURTHER, DISTRIBUTOR WILL NOT GIVE ANY SUCH GUARANTEE OR WARRANTY TO ANY THIRD
PARTIES ON BEHALF OF PURDUE.

ARTICLE VII

INTELLECTUAL PROPERTY

     7.1 Limited Intellectual Property Rights. Distributor acknowledges that by entering into this
Agreement, Distributor will not have, assert or acquire any right, title, license, interest,
waiver, release, right of reference, authorization or covenant, express or implied, in or to any
Purdue intellectual property or other proprietary rights of Purdue, except as may be necessary for
Distributor to distribute the Product as explicitly provided for in this Agreement.

     7.2 No Improvements. Distributor will not make any improvements or modifications to the Products.

     7.3 Improvements. Any improvements to the Branded Products or the Products will be the sole and
exclusive property of Purdue, and Purdue will have the exclusive right to file for intellectual
property protection for such improvements.

ARTICLE VIII

INDEMNIFICATION; LIMITATIONS ON LIABILITY

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

24

 

     8.1 Purdue Indemnity. Purdue will indemnify, defend, save, protect, and hold harmless Distributor
and its Affiliates and their respective directors, officers, employees, and agents
(“Distributor Indemnitees”) from and against any and all losses, claims, damages,
liabilities, costs and expenses (including reasonable attorneys’ fees and expenses and court costs)
(collectively, “Losses”) resulting or arising from any Third Party claims, suits, actions,
proceedings or litigation (“Third Party Claims”) arising from or in connection with:

               (a) Purdue’s negligence or willful misconduct in performing any of its obligations under this
Agreement; or

               (b) a breach by Purdue of any of its representations, warranties, covenants or agreements
under this Agreement;

provided, however, that in all cases referred to in this Section 8.1, Purdue will
not be liable to indemnify Distributor for any Losses of Distributor to the extent that such Losses
of Distributor were caused by: (i) the negligence or willful misconduct or wrongdoing of
Distributor or (ii) any breach by Distributor of its representations, warranties, covenants or
agreements under this Agreement.

     8.2 Distributor Indemnity. Distributor will indemnify, defend, save, protect, and hold harmless
Purdue and its Affiliates and their respective directors, officers, employees, and agents
(collectively, the “Purdue Indemnitees”) from and against any and all Losses resulting or
arising from any Third Party Claims arising from or in connection with:

               (a) Distributor’s negligence or willful misconduct in performing any of its obligations under
this Agreement;

               (b) a breach by Distributor of any of its representations, warranties, covenants or agreements
under this Agreement; or

               (c) any action against Purdue based upon dissemination of information by Distributor or its
Affiliates concerning any product which contains oxycodone;

provided, however, that in all cases referred to in this Section 8.2, Distributor
will not be liable to indemnify Purdue for any Losses of Purdue to the extent that such Losses of
Purdue were caused by: (i) the negligence or willful misconduct or wrongdoing of Purdue or (ii)
any breach by Purdue of its representations, warranties, covenants or agreements under this
Agreement.

     8.3 Procedure for Indemnification.

          8.3.1 Notice. In the case of a Third Party Claim as to which a Party (the
“Indemnifying Party”) may be obligated to provide indemnification pursuant to this
Agreement, such Party seeking indemnification hereunder (the “Indemnitee”) will notify the
Indemnifying Party in writing of the Third Party Claim (and specifying in reasonable detail the
factual basis for the Third Party Claim and, to the extent known, the amount of the Third Party
Claim) promptly

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

25

 

after becoming aware of such Third Party Claim; provided, however,
that failure to give such notification will not affect the indemnification provided hereunder
except to the extent the Indemnifying Party will have been actually prejudiced as a result of such
failure.

          8.3.2 Defense of Claim.

               (a) If a Third Party Claim is made against an Indemnitee, the Indemnifying Party will be
entitled to assume the defense of the Indemnitee by providing written
notice to the Indemnitee of its intention to assume the defense of such Third Party Claim (at
the expense of the Indemnifying Party) within thirty (30) calendar days after receipt of written
notice from the Indemnitee of such Third Party Claim, with counsel selected by the Indemnifying
Party and reasonably satisfactory to the Indemnitee for so long as the Indemnifying Party is
conducting a good faith and diligent defense.

               (b) Should the Indemnifying Party so elect to assume the defense of the Indemnitee, the
Indemnifying Party will not be liable to the Indemnitee for any legal or other expenses
subsequently incurred by the Indemnitee in connection with the defense thereof; provided,
that if under applicable standards of professional conduct a conflict of interest exists between
the Indemnifying Party and the Indemnitee in respect of such claim, such Indemnitee will have the
right to employ separate counsel to represent such Indemnitee with respect to the matters as to
which a conflict of interest exists, and in that event the reasonable fees and expenses of such
separate counsel will be paid by such Indemnifying Party; provided, further, that
the Indemnifying Party will only be responsible for the reasonable fees and expenses of one
separate counsel for such Indemnitee.

               (c) If the Indemnifying Party assumes the defense of the Indemnitee, the Indemnitee will have
the right to participate in such defense and to employ counsel, at its own expense, separate from
the counsel employed by the Indemnifying Party.

               (d) If the Indemnifying Party assumes the defense of the Indemnitee, the Indemnifying Party
will promptly supply to the Indemnitee copies of all correspondence and documents relating to or in
connection with such Third Party Claim and keep the Indemnitee informed of developments relating to
or in connection with such Third Party Claim, as may be reasonably requested by the Indemnitee
(including providing to the Indemnitee on reasonable request updates and summaries as to the status
thereof).

               (e) If the Indemnifying Party assumes the defense of the Indemnitee, the Indemnitee will, and
will cause all Distributor Indemnitees or Purdue Indemnitees, as the case may be, to reasonably
cooperate with the Indemnifying Party in the defense thereof (including making documents and
records available for review and copying and making Persons within its/his/her control available
for pertinent testimony).

               (f) If the Indemnifying Party does not elect to assume the defense of the Indemnitee or does
not provide written acknowledgement of the defense of the Indemnitee within the 30-day period set
forth in Section 8.3.2(a), or if a good faith and diligent defense is not being or

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

26

 

ceases to be conducted by the Indemnifying Party, the Indemnitee will have the right, at the reasonable expense
of the Indemnifying Party, after three (3) Business Days’ notice to the Indemnifying Party of its
intent to do so, to undertake the defense of the Indemnitee (at the reasonable expense of the
Indemnifying Party) with counsel reasonably selected by the Indemnitee, and to compromise or settle
such Third Party Claim, with the Indemnifying Party’s reasonable consent (which consent will not be
unreasonably withheld, delayed or conditioned).

          8.3.3 Settlement of Claims. If the Indemnifying Party acknowledges in writing its
obligation to indemnify the Indemnitee for a Third Party Claim, the Indemnitee will agree (which
agreement will not be unreasonably withheld, delayed or conditioned) to a reasonable settlement,
compromise or discharge of such Third Party Claim that the Indemnifying Party may recommend;
provided, however, that, without the Indemnitee’s prior written consent, the
Indemnifying Party will not consent to any settlement, compromise or discharge (including the
consent to entry of any judgment), and the Indemnitee may refuse to agree to any such settlement,
compromise or discharge, that provides for injunctive or other non-monetary relief affecting the
Indemnitee. If the Indemnifying Party acknowledges in writing its obligation to indemnify the
Indemnitee for a Third Party Claim, the Indemnitee will not (unless required by law) admit any
liability with respect to, or settle, compromise or discharge (“Indemnitee Settlement”),
such Third Party Claim without the Indemnifying Party’s prior written consent (which consent will
not be unreasonably withheld, delayed or conditioned) and if such consent is not received, then the
Indemnifying Party will have no obligation or liability under this Article VIII for any Indemnitee
Settlement.

     8.4 Limitations on Liability. Nothing in this Article VIII will act to negate any obligation under
common law of either Party to mitigate damages with respect to any Third Party Claim for which such
Party is seeking indemnification from the other Party hereunder.

ARTICLE IX

COMPLIANCE WITH GOVERNMENTAL AUTHORITY REGULATIONS

     9.1 Governmental Authority Communications. Purdue will be responsible for all communications with
any Governmental Authority relating to Purdue’s manufacturing activities under this Agreement and
will have the responsibility to communicate with any Governmental Authority concerning the
marketing, distribution, or sale of the Products (except as otherwise required by applicable Law);
provided, however, Distributor will have the responsibility (a) to communicate with
any Governmental Authority concerning all obligations for federal or state governmental rebate
reporting and payments required thereunder, (b) for all price reporting for the Products to any and
all Governmental Authorities, as well as to any Third Party pricing publications, and (c) for all
rebates, price protection claims and payments to Medicaid, Medicare, PBMs (pharmacy benefit
managers) and other payors under Distributor’s NDC number, whether required by contract or Law, for
the Products, and Purdue will provide Distributor with copies of all correspondence from the FDA
authorizing the marketing, distribution or sale of the Products. In addition to the foregoing,
Purdue will be responsible for reviewing, processing, and responding

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

27

 

to all regulatory communications relevant to Product quality, including communications relating to product defects,
adverse event reports and medical inquiries relating to product complaints.

     9.2 Governmental and Regulatory Inspections. Each Party will notify the other Party of any
inspections by any Governmental Authorities of the premises where the Product is being
manufactured, tested or stored, to the extent such inspection relates to the manufacture, storage
or distribution of the Products, within five Business Days after such inspection, and will provide
to the other Party copies of all Forms 483 or other similar notifications of observations relating
to the production, testing, storage, use or sale of the Products, redacted as necessary with respect to
any portions of the Form 483 not pertaining to the Products, within five Business Days after they
are received by or on behalf of a Party from the FDA or any Governmental Authority. All notices
sent to a Party pursuant to this Section 9.2 will be sent to such Party in accordance with the
Quality Agreement.

          9.2.1 Voluntary Recalls. Each Party will notify the other Party in the event that
such Party determines that any Product already in interstate commerce in the Territory presents a
risk of injury or gross deception or is otherwise defective and that recall of such Product is
appropriate (a “Voluntary Recall”), and Purdue solely, after consultation with Distributor,
will make the decision whether to initiate a Voluntary Recall and will control all recall
activities and the Parties will follow the Product recall procedure set forth in the Quality
Agreement.

               (a) If Distributor requests a Voluntary Recall, Distributor will be responsible for all
expenses incurred by Purdue in connection with its cooperation in facilitating such Voluntary
Recall, except to the extent that such Voluntary Recall is attributable to a breach by Purdue of
its representations, warranties, covenants or agreements under this Agreement (in which case, to
such extent, Purdue will be responsible for the expenses associated with any such Voluntary Recall,
including any reasonable out of pocket expenses incurred by Distributor in connection with its
cooperation in facilitating such Voluntary Recall).

               (b) If Purdue requests a Voluntary Recall, Purdue will be responsible for all expenses of such
Voluntary Recall (including any reasonable out of pocket expenses incurred by Distributor in
connection with its cooperation in facilitating such Voluntary Recall), except to the extent that
such Voluntary Recall is attributable to a breach by Distributor of its representations,
warranties, covenants or agreements under this Agreement (in which case, to such extent,
Distributor will be responsible for the expenses associated with any such Voluntary Recall,
including any reasonable out of pocket expenses incurred by Purdue in connection with its
cooperation in facilitating such Voluntary Recall).

               (c) Any expenses incurred by either Party in connection with a Voluntary Recall will not be
included in any calculation of Net Sales for any Product.

          9.2.2 Involuntary Recalls. In the event that any applicable Governmental Authority
should issue a request, directive or order that a Product be recalled (“Involuntary

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

28

 

Recall”), Purdue will control all recall activities and the Parties will follow the Product
recall procedure set forth in the Quality Agreement.

               (a) In the event of an Involuntary Recall of any Product inventory (e.g., batch recall),
Purdue will be responsible for all expenses of such Involuntary Recall (including any reasonable
out-of-pocket expenses incurred by Distributor in connection with its cooperation in facilitating
such Involuntary Recall), except to the extent that such Involuntary Recall is attributable to a
breach by Distributor of its representations, warranties, covenants or agreements under this
Agreement (in which case to such extent Distributor will be responsible for the expenses
associated with any such Involuntary Recall, including any reasonable out-of-pocket expenses
incurred by Purdue in connection with its cooperation in facilitating such Involuntary Recall).

               (b) Any expenses incurred by either Party in connection with such an Involuntary Recall will
not be included in any calculation of Net Sales for any Product.

     9.3 Quality Agreement. The Quality Agreement will include protocols and specific responsibilities
for handling all Product quality complaints, adverse event reports and professional medical service
inquiries in accordance with Purdue’s standard operating procedures and in conformity with
applicable Laws.

ARTICLE X

CONFIDENTIALITY

     10.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise
agreed to in writing, Distributor and Purdue each agree that, until the later of (i) the
termination of this Agreement and (ii) ten (10) years after the date of disclosure, each of
Distributor or Purdue, upon receiving or learning of any Confidential Information of the other
Party, will keep such Confidential Information confidential and otherwise will not disclose or use
such Confidential Information for any purpose other than as provided for in this Agreement. For
the purposes of this Agreement, the existence and terms of this Agreement and the Settlement
Agreement shall be deemed Confidential Information. The Receiving Party will advise its
Affiliates, directors, officers, employees, agents, consultants, lenders and professional advisors
who might have access to the Disclosing Party’s Confidential Information of the confidential nature
thereof and agrees that its Affiliates, directors, officers, employees, agents and consultants,
lenders and professional advisors will be bound by the terms of this Agreement. The Receiving
Party will not disclose any Confidential Information of the Disclosing Party to any Affiliate,
director, officer, employee, agent, consultant, lender or professional advisor who does not have a
need to know such Confidential Information.

     10.2 Authorized Disclosure. The Receiving Party may disclose Disclosing Party’s Confidential
Information to Receiving Party’s Affiliates, directors, officers, employees, agents and
consultants, lenders and professional advisors who need to receive the Confidential Information in
order to further the activities contemplated in this Agreement, and who are made

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

29

 

aware of the confidential nature of the Confidential Information. The Receiving Party must (i) enforce the
terms of this Article X as to its respective Affiliates, directors, officers, employees, agents,
consultants, lenders and professional advisors; (ii) take such action to the extent reasonably
necessary to cause its Affiliates, directors, officers, employees, agents, consultants, lenders and
professional advisors to comply with the terms and conditions of this Article X; and (iii) be
responsible and liable for any breach of the provisions of this Article X by it or its Affiliates,
directors, officers, employees, agents, consultants, lenders and professional advisors. Each Party
will take reasonable precautions to safeguard the Confidential Information of the other Party.
Each Party will also have the right to make disclosures of such portions of the other Party’s
Confidential Information to the DEA or to any other Governmental Authorities where such disclosure
is necessary for such Party to perform its obligations under this Agreement. In addition, the Receiving Party may disclose those portions
of the Disclosing Party’s Confidential Information required to be disclosed by legal process;
provided, in each case the Receiving Party, to the extent it is lawfully able to do so,
promptly informs the Disclosing Party, uses reasonable efforts to limit the disclosure and
maintains the confidentiality to the extent possible and permits the Disclosing Party to attempt by
appropriate legal means to limit such disclosure. Notwithstanding anything to the contrary in this
Section 10.2, Purdue may disclose the terms of this Agreement, upon the prior written consent of
Distributor (not to be unreasonably withheld, conditioned or delayed), to Third Parties in
connection with patent litigation involving the Purdue Patents or the Foreign Patents (each as
defined in the Settlement Agreement) or in connection with settlement discussions and agreements
with alleged infringers of the Purdue Patents or the Foreign Patents, subject to all such Third
Parties keeping the terms of this Agreement strictly confidential in accordance with the terms
hereof.

     10.3 Remedies. Each Party understands and agrees that the wrongful disclosure of the other Party’s
Confidential Information may result in serious and irreparable damage to the other Party hereto,
that the remedy at law for any breach of this covenant may be inadequate, and that the Disclosing
Party will be entitled to seek injunctive relief without the posting of any bond or other security,
enjoining or restraining any Person from any violation or threatened violation of this Article X,
without prejudice to any other rights and remedies to which it may be entitled.

     10.4 Return of Confidential Information. Except as otherwise set forth in this Agreement, upon
termination of this Agreement, the Receiving Party will promptly return all of the Disclosing
Party’s Confidential Information, including all reproductions and copies thereof in any medium,
except that the Receiving Party may retain a reasonable number of archival copies as may be
required by law or its standard procedures.

     10.5 Unauthorized Use. If either Party becomes aware or has knowledge of any unauthorized use or
disclosure of the other Party’s Confidential Information, it will promptly notify the other Party
of such unauthorized use or disclosure.

     10.6 Exclusive Property. All Confidential Information is the sole and exclusive property of the
Disclosing Party and the permitted use thereof by the Receiving Party for purposes

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

30

 

of its performance hereunder will not be deemed a right, license or covenant, either express or implied,
of the Receiving Party to use any such Confidential Information for any other purpose.

ARTICLE XI

TERM; TERMINATION 

     11.1 Term. This Agreement will become effective as of the Effective Date and will expire upon the
later of (i) Purdue’s receipt of the final Net Sales Payment, and (ii) delivery to Purdue of the
last of the certificates required to be delivered pursuant to Sections 4.2 and 4.6, in each case
unless this Agreement is terminated earlier (the “Term”). This Agreement shall
automatically terminate and shall be of no further force and effect if (a) FDA Approval is granted
before or on the same day that either Party has made an election to commence this Agreement, (b)
neither Party has made such election prior to ***, (c) the Settlement Agreement is no longer in
full force or effect or (d) Distributor or any party acting on its behalf or succeeding to its rights attempts to reject or
disavow the Settlement Agreement or any of the other Settlement Documents.

     11.2 Termination. This Agreement may be terminated under any of the following circumstances:

          11.2.1 Material Breach. Failure by either Party to comply in any material respect
with any of its obligations contained in this Agreement with respect to a Product will entitle the
other Party, if it is not in material default hereunder, to give to the Party in default notice
specifying the nature of the default and requiring it to cure such default. If such default is not
cured within fifteen (15) calendar days after the receipt of such notice, the notifying Party will
be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in
addition to any other remedies available to it at law or in equity, to terminate this Agreement by
giving written notice, to take effect immediately upon delivery of such notice. For purposes of
this Section 11.2.1, a material breach of this Agreement will include sales of any AB rated generic
version of Branded Product by Distributor other than during the Selling Period.

          11.2.2 Bankruptcy and Certain Other Events. This Agreement may be terminated, prior
to the expiration of the Term, immediately by either Party upon written notice to the other Party
in the event that the other Party hereto (a) applies for, consents to, becomes the subject of the
appointment of, or the taking of possession by, a receiver, custodian, trustee or liquidator of
itself or of all or a substantial part of its property, (b) makes a general assignment for the
benefit of its creditors, (c) commences a voluntary case under the United States Bankruptcy Code,
as now or hereafter in effect (the “Bankruptcy Code”) or (d) becomes the subject of an
involuntary case under the Bankruptcy Code or similar insolvency proceeding, which case or
proceeding has not been dismissed or otherwise stayed within ninety (90) calendar days.

          11.2.3 Occurrence of Serious Safety Event. If there occurs a serious and unexpected
event with respect to safety issues involving any Product, as a result of which the NDA has been
terminated or suspended in the Territory or any Governmental Authority has directed

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

31

 

discontinuance of development, use or sale of the Product in the Territory, then either Party may terminate this
Agreement by giving written notice, to take effect immediately upon delivery of such notice to the
other Party.

          11.2.4 Settlement Agreement. In the event Distributor fails to comply with any of the
terms or conditions of the Settlement Agreement or this Agreement, including (i) prohibitions on
Distributor and its Affiliates shipping, or causing to be shipped, any AB rated generic version of
Branded Product into interstate commerce for commercial sale in the Territory or (ii) prohibitions
on making offers for sales or customer solicitations for any AB rated generic version of Branded
Product, other than during the Selling Period, then notwithstanding any other provision contained
in this Agreement, Purdue will have the right to terminate this Agreement by giving written notice
to Distributor, such termination to take effect immediately upon the delivery of such notice to
Distributor.

     11.3 Effect of Termination.

          11.3.1 In the event this Agreement is terminated pursuant to Section 11.1 or 11.2, the
termination notice provisions, if any, of such Sections will apply. Upon the effectiveness of
termination pursuant to Section 11.1 or 11.2, Distributor will not solicit offers for sale, offer
to sell, sell, ship, or cause to be shipped, the Product into interstate commerce for commercial
sale in the Territory. At Purdue’s option, Distributor will within five Business Days after the
related termination effective date (a) return all remaining inventory to Purdue, or (b) destroy all
remaining inventory, in each case at Distributor’s sole cost and expense.

          11.3.2 In the event of any termination, Distributor will be responsible to pay Purdue its
Initial Cost of Goods Sold Payment, Final Cost of Goods Sold Payment, Initial Net Sales Payment and
Final Net Sales Payment, as applicable, on any sales of such Products during the Selling Period.
Upon the conclusion of the Selling Period or upon the termination of this Agreement, Distributor
will immediately stop marketing, selling and distributing Product to the Trade.

          11.3.3 Without limiting either Party’s right to damages for any breach of this Agreement,
neither Purdue nor Distributor will incur any liability to the other solely by reason of the
termination of this Agreement as provided herein, whether for loss of goodwill, anticipated profits
or otherwise.

          11.3.4 Upon termination of this Agreement, the rights granted to Distributor pursuant to
Section 2.1.1 with respect to Products will immediately terminate and each Party and its respective
Affiliates and agents will cease any and all use of Confidential Information of the other Party
relating to the Products.

     11.4 Accrued Rights; Surviving Obligations.

          11.4.1 Termination or relinquishment of this Agreement for any reason will be without
prejudice to any rights that will have accrued to the benefit of either Party prior to such

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

32

 

termination or relinquishment, and such termination or relinquishment will not relieve either Party
from obligations which are expressly indicated to survive termination of this Agreement.

          11.4.2 All of the Parties’ rights and obligations under Articles I (Definitions;
Interpretations), IV (Payments and Reports) (as applicable), VII (Intellectual Property), VIII
(Indemnification; Limitations on Liability), IX (Compliance with Governmental Authority
Regulations), X (Confidentiality), and XII (Miscellaneous Provisions), and Sections 2.2, 11.3
(Effect of Termination) (as applicable) and 11.4 (Accrued Rights; Surviving Obligations) will
survive termination hereof.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

33

 

ARTICLE XII

MISCELLANEOUS PROVISIONS

     12.1 Force Majeure. Each Party will be excused from the performance of its obligations under this
Agreement to the extent that such performance is prevented by a Force Majeure Event and the
non-performing Party promptly provides written notice to the other Party of such inability and of
the period for which such inability is expected to continue. Such excused performance will be
continued so long as the condition constituting a Force Majeure Event continues and the
non-performing Party takes reasonable efforts to remove the condition. For purposes of this
Agreement, a Force Majeure Event will include conditions caused by occurrences beyond the control
of the Parties affected, including an act of God, an act, pronouncement, omission or delay in
acting by any Governmental Authority (including the FDA and the DEA) or the other Party, war, an
act of war, terrorism, insurrection, riot, civil commotion, epidemic, failure or default of public
utilities or common carriers, unavailability of one or more raw materials, labor strike, lockout,
labor disturbance, embargo, fire, earthquake, flood, storm or like catastrophe (each a “Force
Majeure Event”). Notwithstanding the foregoing, nothing in this Section 12.1 will excuse or
suspend the obligation of either Party to make any payment due under this Agreement or to comply
with the Quality Agreement in the manner and at the time provided.

     12.2 Notice. All notices, instructions and other communications hereunder or in connection
herewith will be in writing, will be sent to the addresses below and will be: (a) delivered
personally; (b) sent by registered or certified mail, return receipt requested, postage prepaid;
(c) sent via a reputable nationwide overnight courier service; or (d) sent by facsimile
transmission. Any such notice, instruction or communication will be deemed to have been delivered
(w) upon receipt if delivered by hand, (x) three (3) Business Days after it is sent by registered
or certified mail, return receipt requested, postage prepaid, (y) one (1) Business Day after it is
sent via a reputable nationwide overnight courier service, or (z) when transmitted with electronic
confirmation of receipt, if transmitted by facsimile (if such transmission is on a Business Day;
otherwise, on the next Business Day following such transmission).

For Purdue:

Purdue Pharma L.P.

One Stamford Forum

201 Tresser Boulevard

Stamford, CT 06901-3431

Attention: General Counsel

Fax: (203) 588-6204

with a copy to:

Chadbourne & Parke LLP

30 Rockefeller Plaza

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

34

 

New York, NY 10112

Attention: Stuart D. Baker

Fax: (212) 541-5369

For Distributor:

KV Pharmaceutical Company

2503 South Hanley Road

St. Louis, Missouri 63144

Attention: Paul Brady

Fax: (314) 644-2419

with a copy to:

Locke Lord Bissell & Liddell

3 World Financial Center

New York, New York 10281-2101

Attention: John F. Sweeney

Fax No.: (212) 303-2754

     12.3 Assignment. This Agreement is binding upon and will inure to the benefit of each Party hereto
and each of its successors and permitted assigns. Distributor may not assign (including by way of
merger, acquisition, consolidation, sale of stock, sale of assets, operation of law or otherwise)
this Agreement without the prior written consent of Purdue which may be withheld in Purdue’s sole
discretion; provided, however, that, in the event such consent is granted, no such
assignment shall in any manner limit or impair the obligations of Distributor hereunder; and
provided further, however, that any party that acquires this Agreement as a result
of such assignment and any Affiliate of such party will thereby become subject to the terms and
conditions of this Agreement. If notwithstanding the above, there is a Change of Control of
Distributor, this Agreement shall be deemed to be assigned and each Person or entity directly or
indirectly controlling Distributor and each Affiliate of such Person or entity shall become subject
to the terms and conditions of this Agreement and shall agree in writing to be bound hereby, and
Distributor shall remain primarily liable for the performance of all its obligations under this
Agreement and for causing its assignees to act in a manner consistent herewith. For purposes of
this Section 12.2, “Change of Control” shall mean the transfer or disposition (including by
way of merger, acquisition, consolidation, sale of stock, sale of assets, operation of law or
otherwise) of more than 50% of the total assets, equity interests, or voting power of Distributor
or the appointment of a trustee, receiver, examiner or liquidator for Distributor. Any assignment
or attempted assignment by Distributor of this Agreement or the rights and obligations granted to
Distributor hereunder in contravention of the provisions of this Section 12.3 will be void and will
have no force or effect.

     12.4 No Waiver. Any term or condition of this Agreement may be waived at any time by the Party
that is entitled to the benefit thereof, but no such waiver will be effective unless set

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

35

 

forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. No
waiver by any Party of any term or condition of this Agreement, in any one or more instances, will
be deemed to be or construed as a waiver of the same or any other term or condition of this
Agreement on any future occasion. Except as expressly set forth in this Agreement, all rights and
remedies available to a Party, whether under this Agreement or afforded by Law or otherwise, will
be cumulative and not in the alternative to any other rights or remedies that may be available to
such Party.

     12.5 Injunction. Distributor acknowledges and agrees that Distributor’s violation or breach of
this Agreement, including by making sales (i) of any AB rated generic version of the Branded
Product other than during the Selling Period or (ii) in excess of the Supply Amount or after the
conclusion of the Selling Period would cause Purdue to suffer substantial damages and irreparable
harm that could not adequately be remedied by an action at law, including causing Purdue to be in
violation or breach of, or severely disadvantaged under, certain material agreements Purdue has
entered into with Third Parties. Accordingly, Distributor agrees that Purdue will be entitled,
without limitation, to specific performance or preliminary or permanent injunctive relief without
the requirement of posting a bond in any action, hearing, litigation or suit for violation or
breach of this Agreement, such rights and remedies being in addition to all other rights and
remedies available to Purdue at law, in equity or otherwise, and Distributor will not assert in
opposition to Purdue’s request for any equitable relief that Purdue has an adequate remedy at law.
Distributor agrees that jurisdiction and venue for any such action under this Section 12.5 exists
in the United States District Court for the Southern District of New York, and waives any and all
defenses based on personal jurisdiction, subject matter jurisdiction and venue, or to the extent
any such waiver is not enforceable, Distributor agrees not to assert such defense.

     12.6 Governing Law. This Agreement, including the interpretation, performance, enforcement, breach
or termination thereof and any remedies relating thereto, will be governed by and interpreted in
accordance with the laws of the State of New York, without regard to its conflicts of law rules.

     12.7 Entirety of Agreement. This Agreement, the Quality Agreement and the Settlement Agreement,
and all schedules and exhibits attached hereto and thereto, set forth the complete, final and
exclusive agreement and all the covenants, promises, agreements, warranties, representations,
conditions and understandings between the Parties hereto and supersede and terminate all prior
covenants, promises, agreements, warranties, representations, conditions and understandings between
the Parties. There are no covenants, promises, agreements, warranties, representations, conditions
or understandings, either oral or written, between the Parties other than as are set forth herein
and therein. No subsequent alteration, amendment, change or addition to this Agreement or the
Quality Agreement will be binding upon the Parties unless reduced to writing and signed by an
authorized officer of each Party.

     12.8 Public Announcements. The form and content of any public announcement, including any press
release, to be made by one Party regarding this Agreement, or the subject matter contained herein,
will be subject to the prior written consent of the other Party, provided

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

36

 

that this provision will not preclude a Party from making disclosures required by applicable Law (including
disclosure requirements under federal or state securities laws, NASDAQ or any stock exchange
requirements, or otherwise), in which event the disclosing Party will give the other Party
reasonable advance notice of at least two (2) Business Days to review and comment on such
disclosure. Notwithstanding the foregoing, after the earlier of (i) the date of the Consent
Judgment (as such term is defined in the Settlement Agreement) and (ii) ninety (90) days after the
date of the Settlement Agreement, either Party may announce that this Agreement has been entered into. The
disclosing Party will use Commercially Reasonable Efforts to obtain confidential treatment of such
information that is required to be disclosed by Law. The Parties shall also consult with each
other with respect to any disclosures required to be made to the FDA as a result of this Agreement.

     12.9 Relationship of the Parties. Neither Party will have any responsibility for the hiring,
termination or compensation of the other Party’s employees or for any employee benefits of such
employee. No employee or representative of a Party will have any authority to bind or obligate the
other Party to this Agreement for any sum or in any manner whatsoever, or to create or impose any
contractual or other liability on the other Party without said Party’s approval. For all purposes,
and notwithstanding any other provision of this Agreement to the contrary, Distributor’s legal
relationship to Purdue under this Agreement will be that of independent contractor. This Agreement
is not a partnership agreement and nothing in this Agreement will be construed to establish a
relationship of partners or joint venturers between the Parties.

     12.10 Non-Solicitation of Employees. During the Term of this Agreement, neither Party may,
directly or indirectly, recruit or solicit any employee of the other Party who became known to the
other Party through contact or interactions for the purposes of performing this Agreement, without
the prior consent of the other Party, except pursuant to general solicitations not targeted at such
employees.

     12.11 Severability. In the event that any one or more of the provisions contained herein, or the
application thereof in any circumstances, is held to be invalid, illegal or unenforceable in any
respect for any reason, the Parties will negotiate in good faith with a view to the substitution
therefor of a suitable and equitable solution in order to carry out, so far as may be valid and
enforceable, the intent and purpose of such invalid provision; provided, however,
that the validity, legality and enforceability of any such provision in every other respect and of
the remaining provisions contained herein will not be in any way impaired thereby, it being
intended that all of the rights and privileges of the Parties hereto will be enforceable to the
fullest extent permitted by Law.

     12.12 Books and Records. Any books and records to be maintained under this Agreement by a Party or
its Affiliates will be maintained in accordance with GAAP.

     12.13 Expenses. Each of Purdue and Distributor will bear its own direct and indirect expenses
incurred in connection with the negotiation and preparation of this Agreement and the Quality
Agreement and, except as set forth in this Agreement or the Quality Agreement, the performance of
the obligations contemplated hereby and thereby.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

37

 

     12.14 No Third Party Beneficiary. This Agreement will be binding upon and inure solely to the
benefit of the Parties hereto, their successors and permitted assigns, and nothing in this
Agreement, express or implied, is intended to or will confer upon any other Person or Persons any
rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement.

     12.15 Further Actions. Each Party will execute, acknowledge and deliver such further instruments,
and do all such other acts, as may be necessary or appropriate in order to carry out the purposes
and intent of this Agreement.

     12.16 Counterparts; Facsimile Signatures. This Agreement may be executed in counterparts, each of
which counterparts, when so executed and delivered, will be deemed to be an original, and both of
which counterparts, taken together, will constitute one and the same instrument even if both
Parties have not executed the same counterpart. Signatures provided by facsimile transmission or
via pdf copy bearing a signature on behalf of a Party hereto shall be legal and binding on such
Party and will be deemed to be original signatures.

     12.17 Headings. The headings for each Article and Section in this Agreement have been inserted for
convenience of reference only and are not intended to limit or expand on the meaning of the
language contained in the particular Article or Section, and will be of no force or effect in
construing or interpreting any of the provisions of this Agreement.

[The next page is the signature page.]

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

38

 

     IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed in multiple
counterparts by its duly authorized representative.

	 	 	 	 	 
	 	PURDUE PHARMA L.P.
 	 
	 	By:  	Purdue Pharma Inc., its general partner

 	 
	 	By:  	/s/
Edward B. Mahony	 
	 	 	Name:  	Edward B. Mahony	 
	 	 	Title:  	EVP, CFO & Treasurer	 
	 
	 	KV PHARMACEUTICAL COMPANY

 	 
	 	By:  	/s/
Paul T. Brady	 
	 	 	Name:  	Paul T. Brady	 
	 	 	Title:  	Corporate Vice President, B.D.	 
	 

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

39

 

Schedule 1.1A

BRANDED PRODUCTS

OxyContin® (oxycodone hydrochloride controlled-release) Tablets, under NDA number 20-553, together
with all amendments and supplements thereto, including all existing or future dosage strengths, all
other existing or future formulations, all improvements thereon, and all other existing or future
indications.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

Schedule 1.1B

COST OF GOODS SOLD

The following table sets forth the cost of goods sold per Bottle in each dosage strength of Product
to be supplied under the Distribution and Supply Agreement.

	 	 	 
	Dosage	 	 
	Strength	 	Cost Per Bottle
	10 mg

	 	$***
	15 mg

	 	$***
	20 mg

	 	$***
	30 mg

	 	$***
	40 mg

	 	$***
	60 mg

	 	$***
	80 mg

	 	$***

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

Schedule 1.1C

PRODUCTS

Product definition: Authorized generic versions of 10 mg, 20 mg, 40 mg and 80 mg OxyContin® (oxycodone hydrochloride controlled-release) Tablets, under NDA number 20-553, together with all
amendments and supplements thereto, but specifically excluding all other existing or future dosage
strengths.

	 	 	 
	NDC	 	Description
	58177-677-04

	 	10 mg 100 ct
	58177-678-04

	 	15 mg 100 ct
	58177-679-04

	 	20 mg 100 ct
	58177-680-04

	 	30 mg 100 ct
	58177-681-04

	 	40 mg 100 ct
	58177-682-04

	 	60 mg 100 ct
	58177-683-04

	 	80 mg 100 ct

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

Schedule 1.1D

RISK MANAGEMENT PROGRAM

Distributor must comply with the following Risk Management Program activities prior to and at all
times during all marketing, making arrangements for selling or distributing of the Products in the
Territory:

               (a) Distributor will provide to Purdue’s Corporate Security Department (contact information
below in clause (k)) a detailed report of any disruption to, loss from or imminent threat to supply
chain integrity, from receipt of Product from Purdue to distribution of Product to the Trade, upon
becoming aware of such event, including:

               (i) Attempted or actual theft or loss of any controlled substance, or packaging
materials, such as bottles, Labels, etc. relating to Product; and

               (ii) Counterfeit Product or packaging for Product;

               (b) Distributor will provide to Purdue’s Controlled Substance Act Compliance Officer (contact
information below in clause (k)):

               (i) Reports of any variances to Distributor’s standard operating procedures for Product
handling or record keeping within facilities under Distributor’s control; and

               (ii) Results of DEA inspections of Distributor’s facilities that contain Product
(provided that Distributor will not be required to provide the results of any inspection
that is unrelated, in whole or in part, to Product or any scheduled products and that could
not reasonably be construed to affect Product in any manner whatsoever).

               (c) Upon Purdue’s request, Distributor will produce as soon as possible, but in no event later
than three Business Days after such request, a complete and accurate listing of all distribution
facilities/entities to which Product has been shipped, including legible copies of the relevant DEA
222 forms.

               (d) If Distributor telemarkets the Product directly to any pharmacy, Distributor will
distribute to these pharmacies Purdue’s written materials dealing with prevention of abuse and
diversion, and materials for education on the proper management of pain.

               (e) Distributor will only market or sell the Product to buying officers of wholesalers,
pharmacy retailers and other distribution channels such as mail order pharmacies, long-term care
facilities and closed provider pharmacies.

               (f) Distributor will not market or sell the Product to health care professionals, hospitals or
any patient setting that would be equivalent to a pharmaceutical sales representative detail call.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

               (g) Distributor will not market the Product to consumers, patients, or potential patients,
directly or indirectly, or through any direct-to-consumer advertising.

               (h) Distributor will make available to its customers for the Product the “Patient Package
Insert” or “Medication Guide”, whichever is applicable.

               (i) Distributor will cooperate with Purdue in the timely adoption and implementation of
security features for the Product as they are developed and implemented in Purdue’s risk management
program for its Branded Products.

               (j) If Distributor becomes aware of any abuse or diversion of Product, Distributor will notify
Purdue’s Department of Risk Management & Health Policy (contact information below in clause (k)).

               (k) Contact information:

(i) Purdue’s Corporate Security Department

Mark Geraci

Vice President, Chief Security Officer

Tel: (203) 588-8454

Fax: (203) 588-6035

(ii) Purdue’s Controlled Substance Act Compliance Officer

John Crowley

Executive Director, Controlled Substance Act Compliance

Tel: (203) 588-8613

Fax: (203) 588-6204

(iii) Purdue’s Department of Risk Management & Health Policy

J. David Haddox, D.D.S., M.D.

Vice President, Risk Management & Health Policy

Tel: (203) 588-7667

Fax: (203) 588-6242

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

Schedule 3.1.1

SUPPLY AMOUNT

	 	 	 	 	 
	 	 	 	 	Approximate
	NDC	 	Description	 	Number of Bottles
	58177-677-04

	 	10 mg 100 ct
	 	***
	58177-678-04

	 	15 mg 100 ct
	 	***
	58177-679-04

	 	20 mg 100 ct
	 	***
	58177-680-04

	 	30 mg 100 ct
	 	***
	58177-681-04

	 	40 mg 100 ct
	 	***
	58177-682-04

	 	60 mg 100 ct
	 	***
	58177-683-04

	 	80 mg 100 ct
	 	***

INITIAL SUPPLY AMOUNT

	 	 	 	 	 
	 	 	 	 	Approximate
	NDC	 	Description	 	Number of Bottles
	58177-677-04

	 	10 mg 100 ct
	 	***
	58177-678-04

	 	15 mg 100 ct
	 	***
	58177-679-04

	 	20 mg 100 ct
	 	***
	58177-680-04

	 	30 mg 100 ct
	 	***
	58177-681-04

	 	40 mg 100 ct
	 	***
	58177-682-04

	 	60 mg 100 ct
	 	***
	58177-683-04

	 	80 mg 100 ct
	 	***

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

REMAINDER SUPPLY AMOUNT

	 	 	 	 	 
	 	 	 	 	Approximate
	NDC	 	Description	 	Number of Bottles
	58177-677-04

	 	10 mg 100 ct
	 	***
	58177-678-04

	 	15 mg 100 ct
	 	***
	58177-679-04

	 	20 mg 100 ct
	 	***
	58177-680-04

	 	30 mg 100 ct
	 	***
	58177-681-04

	 	40 mg 100 ct
	 	***
	58177-682-04

	 	60 mg 100 ct
	 	***
	58177-683-04

	 	80 mg 100 ct
	 	***

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

Schedule 3.1.4

INITIAL LABEL

INDICIA

Each tablet will be marked “AG” on one side and the dosage strength (e.g. 10) on the other.

 

			
	***	 	Certain confidential information contained in this document, marked with three asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.Exhibit 10.1

EXHIBIT 10.1

EXECUTION COPY

JPMorgan Chase Bank, National Association

P.O. Box 161

60 Victoria Embankment

London EC4Y 0JP

England

June 4, 2009

			
	To:	 	Exterran Holdings, Inc.

16666 Northchase Drive

Houston, Texas 77060

Attention: Treasurer

Telephone No.: (281) 836-7000

Facsimile No.: (281) 836-8106

Re: Call Option Transaction

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and
conditions of the call option transaction entered into between JPMorgan Chase Bank, National
Association, London Branch (“Dealer”) and Exterran Holdings, Inc. (“Counterparty”) as of the Trade
Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as
referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any
previous agreements and serve as the final documentation for this Transaction.

The definitions and provisions contained in the 2002 ISDA Equity Derivatives Definitions (the
"Equity Definitions”), as published by the International Swaps and Derivatives Association, Inc.
(“ISDA”) are incorporated into this Confirmation. In the event of any inconsistency between the
Equity Definitions and this Confirmation, this Confirmation shall govern. Certain defined terms
used herein have the meanings assigned to them in the Prospectus dated June 3, 2009, as
supplemented by the Prospectus Supplement dated June 4, 2009 (as so supplemented, the “Prospectus”)
relating to the USD 325,000,000 principal amount of 4.25% Convertible Senior Notes due 2014 (the
"Convertible Notes” and each USD 1,000 principal amount of Convertible Notes, a “Convertible Note”)
issued by Counterparty pursuant to the Indenture to be dated as of June 10, 2009 (the “Base
Indenture”), as supplemented by a Supplemental Indenture thereto (the “Supplemental Indenture”) to
be dated June 10, 2009, between Counterparty and Wells Fargo Bank, National Association, as trustee
(the Base Indenture as so supplemented, the “Indenture”). In the event of any inconsistency
between the terms defined in the Prospectus, the Indenture and this Confirmation, this Confirmation
shall govern. The parties acknowledge that this Confirmation is entered into on the date hereof
with the understanding that (i) definitions set forth in the Indenture which are also defined
herein by reference to the Indenture and (ii) sections of the Indenture that are referred to herein
will conform to the descriptions thereof in the Prospectus. If any such definitions in the
Indenture or any such sections of the Indenture differ from the descriptions thereof in the
Prospectus, the descriptions thereof in the Prospectus will govern for purposes of this
Confirmation. The parties further acknowledge that the Indenture section numbers used herein are
based on the draft of the Indenture last reviewed by Dealer as of the date of this Confirmation,
and if any such section numbers are changed in the Indenture as executed, the parties will amend
this Confirmation in good faith to preserve the intent of the parties. For the avoidance of doubt,
references to the Base Indenture or Supplemental Indenture, as the case may be, herein are
references to the Base Indenture or the Supplemental Indenture, as the case may be, as in effect on
the date of its execution and if the Base Indenture or the Supplemental Indenture is amended
following such date, any such amendment will be disregarded for purposes of this Confirmation
unless the parties agree otherwise in writing.

JPMorgan Chase Bank, National Association

Organised under the laws of the United States as a National Banking Association

Main Office 1111 Polaris Parkway, Columbus, Ohio 43271

Registered as a branch in England & Wales branch No. BR000746

Registered Branch Office 125 London Wall, London EC2Y 5AJ

Authorised and regulated by the Financial Services Authority

 

 

 

Each party is hereby advised, and each such party acknowledges, that the other party has
engaged in, or refrained from engaging in, substantial financial transactions and has taken other
material actions in reliance upon the parties’ entry into the Transaction to which this
Confirmation relates on the terms and conditions set forth below.

1. This Confirmation evidences a complete and binding agreement between Dealer and Counterparty as
to the terms of the Transaction to which this Confirmation relates. This Confirmation shall
supplement, form a part of, and be subject to an agreement in the form of the 2002 ISDA Master
Agreement (the “Agreement”) as if Dealer and Counterparty had executed an agreement in such form
(but without any Schedule except for the election of the laws of the State of New York as the
governing law (without reference to the choice of law doctrine)) on the Trade Date. In the event
of any inconsistency between provisions of the Agreement and this Confirmation, this Confirmation
will prevail for the purpose of the Transaction to which this Confirmation relates. The parties
hereby agree that no Transaction other than the Transaction to which this Confirmation relates
shall be governed by the Agreement.

2. The terms of the particular Transaction to which this Confirmation relates are as follows:

	 	 	 	 	 
	General Terms:	 	 
	 
	 	 	 	 
	 

	 	Trade Date:
	 	June 4, 2009 
	 
	 	 	 	 
	 

	 	Effective Date:
	 	The third Exchange Business Day immediately prior to the Premium Payment Date
	 
	 	 	 	 
	 

	 	Option Style:
	 	“Modified American”, as described under “Procedures for Exercise” below
	 
	 	 	 	 
	 

	 	Option Type:
	 	Call
	 
	 	 	 	 
	 

	 	Buyer:
	 	Counterparty
	 
	 	 	 	 
	 

	 	Seller:
	 	Dealer
	 
	 	 	 	 
	 

	 	Shares:
	 	The common stock of Counterparty, par value USD 0.01 per Share (Exchange symbol
“EXH”)
	 
	 	 	 	 
	 

	 	Number of Options:
	 	325,000. For the avoidance of doubt, the Number of Options shall be reduced by any
Options exercised by Counterparty. In no event will the Number of Options be less
than zero.
	 
	 	 	 	 
	 

	 	Applicable Percentage:
	 	20% 
	 
	 	 	 	 
	 

	 	Option Entitlement:
	 	As of any date, a number equal to the product of the Applicable Percentage and the
Conversion Rate as of such date (as defined in the Supplemental Indenture, but
without regard to any adjustments to the Conversion Rate pursuant to Section 4.04(f)
or (g) or Section 4.06 of the Supplemental Indenture and subject to “Method of
Adjustment” below), for each Convertible Note.
	 
	 	 	 	 
	 

	 	Strike Price:
	 	USD 23.1508 
	 
	 	 	 	 
	 

	 	Premium:
	 	USD 17,881,500 
	 
	 	 	 	 
	 

	 	Premium Payment Date:
	 	June 10, 2009 

 

2

 

	 	 	 	 	 
	 

	 	Exchange:
	 	The New York Stock Exchange
	 
	 	 	 	 
	 

	 	Related Exchange(s):
	 	All Exchanges
	 
	 	 	 	 
	Procedures for Exercise:	 	 
	 
	 	 	 	 
	 

	 	Exercise Period(s):
	 	Notwithstanding anything to the contrary in the Equity Definitions, an Exercise
Period shall occur with respect to an Option hereunder only if such Option is an
Exercisable Option (as defined below) and the Exercise Period shall be, in respect
of any Exercisable Option, the period commencing on, and including, the relevant
Conversion Date and ending on, and including, the Scheduled Valid Day immediately
preceding the first day of the relevant Settlement Averaging Period in respect of
such Conversion Date; provided that in respect of Exercisable Options relating to
Convertible Notes for which the relevant Conversion Date occurs on or after March
15, 2014, the final day of the Exercise Period shall be the Scheduled Valid Day
immediately preceding the Expiration Date.
	 
	 	 	 	 
	 

	 	Conversion Date:
	 	With respect to any conversion of Convertible Notes, the date on which the Holder
(as such term is defined in the Supplemental Indenture) of such Convertible Notes
satisfies all of the requirements for conversion thereof as set forth in Section
4.02(b) of the Supplemental Indenture.
	 
	 	 	 	 
	 

	 	Exercisable Options:
	 	In respect of any Exercise Period (the “Relevant Exercise Period”), the lesser of
(i) the number of Convertible Notes surrendered to Counterparty for conversion on
the first day of the Relevant Exercise Period, and (ii) the Number of Options as of
the first day of the Relevant Exercise Period; provided that if there are any other
Exercisable Options as to which a prior Exercise Period has commenced but no
Exercise Date has yet occurred which would thereby reduce the Number of Options as
of the related Exercise Date (such other Exercisable Options, the “Other Exercisable
Options”), then solely for the purposes of determining the number of Exercisable
Options for the Relevant Exercise Period, the Number of Options on the first day of
the Relevant Exercise Period shall be reduced by such Other Exercisable Options.
	 
	 	 	 	 
	 

	 	 	 	Notwithstanding the foregoing, in no event shall the number of Exercisable Options
exceed the Number of Options.
	 
	 	 	 	 
	 

	 	Expiration Time:
	 	The Valuation Time
	 
	 	 	 	 
	 

	 	Expiration Date:
	 	June 15, 2014, subject to earlier exercise.
	 
	 	 	 	 
	 

	 	Multiple Exercise:
	 	Applicable, as described under Exercisable Options above.
	 
	 	 	 	 
	 

	 	Automatic Exercise:
	 	Applicable; and means that in respect of an Exercise Period, a number of Options not
previously exercised hereunder equal to the number of Exercisable Options shall be
deemed to be exercised on the final day of such Exercise Period for such Exercisable
Options; provided that such Options shall be deemed exercised only if Counterparty
has provided a Notice of Exercise to Dealer.

 

3

 

	 	 	 	 	 
	 

	 	Notice of Exercise:
	 	Notwithstanding anything to the contrary in the Equity Definitions, in order to
exercise any Exercisable Options, Counterparty must notify Dealer in writing before
5:00 p.m. (New York City time) on the Scheduled Valid Day prior to the scheduled
first day of the Settlement Averaging Period for the Exercisable Options being
exercised of (i) the number of such Options, (ii) the scheduled first day of the
Settlement Averaging Period and the scheduled Settlement Date and (iii) if
Counterparty elects a Settlement Method other than Net Share Settlement Method in
accordance with “Settlement Method” below, such notice must include the information,
representations, acknowledgements and agreements required pursuant to “Settlement
Method Election Conditions” below; provided that in respect of Exercisable Options
relating to Convertible Notes with a Conversion Date occurring on or after March 15,
2014, such notice may be given on or prior to the second Scheduled Valid Day
immediately preceding the Expiration Date and need only specify the information
required in clause (i) above, and the information in clause (iii) above, if
applicable, will be provided in a Notice of Final Settlement Method.
	 
	 	 	 	 
	 

	 	Notice of Final Settlement Method:
	 	In order to elect a Settlement Method other than Net Share Settlement for any
Exercisable Options relating to Convertible Notes with a Conversion Date occurring
on or after March 15, 2014, Counterparty must notify Dealer in writing before 5:00
p.m. (New York City time) on or prior to March 15, 2014 of such election, and any
such notice must include the information, representations, acknowledgements and
agreements required pursuant to “Settlement Method Election Conditions” below.
	 
	 	 	 	 
	 

	 	Valuation Time:
	 	At the close of trading of the regular trading session on the Exchange; provided
that if the principal trading session is extended, the Calculation Agent shall
determine the Valuation Time in its reasonable discretion.
	 
	 	 	 	 
	 

	 	Market Disruption Event:
	 	Section 6.3(a) of the Equity Definitions is hereby replaced in its entirety by the
following:
	 
	 	 	 	 
	 

	 	 	 	“‘Market Disruption Event’ means, in respect of a Share, (i) a failure by the
primary United States national or regional securities exchange or market on which
the Shares are listed or admitted to trading to open for trading during its regular
trading session or (ii) the occurrence or existence prior to 1:00 p.m. (New York
City time) on any Scheduled Valid Day for the Shares for more than one half-hour
period in the aggregate during regular trading hours of any suspension or limitation
imposed on trading (by reason of movements in price exceeding limits permitted by
the relevant stock exchange or otherwise) in the Shares or in any options, contracts
or future contracts relating to the Shares.”

 

4

 

	 	 	 	 	 
	Settlement Terms:	 	 
	 
	 	 	 	 
	 

	 	Settlement Method:
	 	For any Exercisable Option, Net Share Settlement; provided that Counterparty may
elect Cash Settlement or Combination Settlement for such Exercisable Option in
accordance with the “Settlement Method Election Conditions” below.
	 
	 	 	 	 
	 

	 	Settlement Method Election Conditions:
	 	In order to elect a Settlement Method other than Net Share Settlement for any
Exercisable Option, the Notice of Exercise or Notice of Final Settlement Method for
such Exercisable Option, as applicable, shall:
	 
	 

	 	 	 	(i) include Counterparty’s election of such other Settlement Method for such
Exercisable Options;
	 
	 	 	 	 
	 

	 	 	 	(ii) if such other Settlement Method is Combination Settlement, specify the fixed
amount of cash per Exercisable Option that is to be delivered to Counterparty (the
“Specified Option Cash Amount”);
	 
	 	 	 	 
	 

	 	 	 	(iii) contain a representation that, on the date of such Notice of Exercise or
Notice of Final Settlement Method, as applicable, Counterparty is not in possession
of any material non-public information with respect to Counterparty or the Shares;
	 
	 	 	 	 
	 

	 	 	 	(iv) contain a representation that Counterparty is electing such other Settlement
Method in good faith and not as part of a plan or scheme to evade the prohibitions
of Rule 10b-5 under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”);
	 
	 	 	 	 
	 

	 	 	 	(v) contain a representation that Counterparty has not entered into or altered any
hedging transaction relating to the Shares corresponding to or offsetting the
Transaction;
	 
	 	 	 	 
	 

	 	 	 	(vi) contain a representation that Counterparty is not electing such other
Settlement Method to create actual or apparent trading activity in the Shares (or
any security convertible into or exchangeable for the Shares) or to raise or depress
or otherwise manipulate the price of the Shares (or any security convertible into or
exchangeable for the Shares); and
	 
	 	 	 	 
	 

	 	 	 	(vii) contain an acknowledgment by Counterparty that (A) any transaction by Dealer
following Counterparty’s election of such other Settlement Method shall be made at
Dealer’s sole discretion and for Dealer’s own account and (B) Counterparty does not
have, and shall not attempt to exercise, any influence over how, when, whether or at
what price to effect such transactions, including, without limitation, the price
paid or received per Share pursuant to such transactions, or whether such
transactions are made on any securities exchange or privately.

 

5

 

	 	 	 	 	 
	 

	 	Net Share Settlement:
	 	If Net Share Settlement is applicable to any Exercisable Option exercised or deemed
exercised hereunder, Dealer will deliver to Counterparty, on the relevant Settlement
Date for each such Exercisable Option, a number of Shares (the “Net Share Settlement
Amount”) equal to the sum, for each Valid Day during the Settlement Averaging Period
for each such Exercisable Option, of (i) the Daily Option Value for such Valid Day,
divided by (ii) the Relevant Price on such Valid Day, divided by (iii) the number of
Valid Days in the Settlement Averaging Period; provided that in no event shall the
Net Share Settlement Amount for any Exercisable Option exceed a number of Shares
equal to the Applicable Limit for such Exercisable Option divided by the Relevant
Price on the last Valid Day of the Settlement Averaging Period.
	 
	 	 	 	 
	 

	 	 	 	Dealer will deliver cash in lieu of any fractional Shares to be delivered with
respect to any Net Share Settlement Share Amount valued at the Relevant Price for
the last Valid Day of the Settlement Averaging Period.
	 
	 	 	 	 
	 

	 	Combination Settlement:
	 	If Combination Settlement is applicable to any Exercisable Option exercised or
deemed exercised hereunder, Dealer will deliver to Counterparty, on the relevant
Settlement Date for each such Exercisable Option:
	 
	 	 	 	 
	 

	 	 	 	(i) an amount of cash (the “Combination Settlement Cash Amount”) equal to the sum,
for each Valid Day during the Settlement Averaging Period for such Exercisable
Option, of (A) an amount (the “Daily Combination Settlement Cash Amount”) equal to
the lesser of (1) the product of the Applicable Percentage and the Specified Option
Cash Amount and (2) the Daily Option Value, divided by (B) the number of Valid Days
in the Settlement Averaging Period; and
	 
	 	 	 	 
	 

	 	 	 	(ii) a number of Shares (the “Combination Settlement Share Amount”) equal to the
sum, for each Valid Day during the Settlement Averaging Period for such Exercisable
Option, of (A) the Daily Option Value on such Valid Day minus Daily Combination
Settlement Cash Amount for such Valid Day, divided by (B) the Relevant Price on such
Valid Day, divided by (C) the number of Valid Days in the Settlement Averaging
Period; provided that if the calculation in clause (A) above results in zero or a
negative number for any Valid Day, the Combination Settlement Share Amount for such
Valid Day shall be deemed to be zero;
	 
	 	 	 	 
	 

	 	 	 	provided that in no event shall the sum of (x) the Combination Settlement Cash
Amount for any Exercisable Option and (y) the Combination Settlement Share Amount
for such Exercisable Option multiplied by the Relevant Price on the last Valid Day
of the Settlement Averaging Period, exceed the Applicable Limit for such Exercisable
Option.
	 
	 	 	 	 
	 

	 	 	 	Dealer will deliver cash in lieu of any fractional Shares to be delivered with
respect to any Combination Settlement Share Amount valued at the Relevant Price for
the last Valid Day of the Settlement Averaging Period.

 

6

 

	 	 	 	 	 
	 

	 	Cash Settlement:
	 	If Cash Settlement is applicable to any Exercisable Option exercised or deemed
exercised hereunder, in lieu of Section 8.1 of the Equity Definitions, Dealer will
pay to Counterparty, on the relevant Settlement Date for each such Exercisable
Option, an amount of cash (the “Cash Settlement Amount”) equal to the sum, for each
Valid Day during the Settlement Averaging Period for such Exercisable Option, of (i)
the Daily Option Value for such Valid Day, divided by (ii) the number of Valid Days
in the Settlement Averaging Period; provided that in no event shall the Cash
Settlement Amount for any Exercisable Option exceed the Applicable Limit for such
Exercisable Option.
	 
	 	 	 	 
	 

	 	Daily Option Value:
	 	For any Valid Day, an amount equal to (i) the Option Entitlement on such Valid Day,
multiplied by (ii) the Relevant Price on such Valid Day less the Strike Price on
such Valid Day; provided that if the calculation contained in clause (ii) above
results in a negative number, the Daily Option Value for such Valid Day shall be
deemed to be zero. In no event will the Daily Option Value be less than zero.
	 
	 	 	 	 
	 

	 	Applicable Limit:
	 	For any Exercisable Option, an amount of cash equal to the Applicable Percentage
multiplied by the excess of (i) the aggregate of (A) the amount of cash, if any,
delivered to the Holder of the related Convertible Note upon conversion of such
Convertible Note and (B) the number of Shares, if any, delivered to the Holder of
the related Convertible Note upon conversion of such Convertible Note multiplied by
the Relevant Price on the last Valid Day of the Settlement Averaging Period for such
Exercisable Option, over (ii) USD 1,000.
	 
	 	 	 	 
	 

	 	Valid Day:
	 	A day on which (i) there is no Market Disruption Event and (ii) trading in the
Shares generally occurs on the Exchange or, if the Shares are not then listed on the
Exchange, on the principal other United States national or regional securities
exchange on which the Shares are then listed or, if the Shares are not then listed
on a United States national or regional securities exchange, on the principal other
market on which the Shares are then traded. If the Shares are not so listed or
traded, “Valid Day” means a Business Day.
	 
	 	 	 	 
	 

	 	Scheduled Valid Day:
	 	A day that is scheduled to be a Valid Day on the principal United States national or
regional securities exchange or market on which the Shares are listed or admitted
for trading. If the Shares are not so listed or admitted for trading, “Scheduled
Valid Day” means a Business Day.
	 
	 	 	 	 
	 

	 	Business Day:
	 	Any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank
of New York is authorized or required by law or executive order to close or be
closed.
	 
	 	 	 	 
	 

	 	Relevant Price:
	 	On any Valid Day, the per Share volume-weighted average price as displayed under the
heading “Bloomberg VWAP” on Bloomberg page EXH.N <equity> AQR (or any successor
thereto) in respect of the period from the scheduled opening time of the Exchange to
the Scheduled Closing Time of the Exchange on such Valid Day (or if such
volume-weighted average price is unavailable, the market value of one Share on such
Valid Day, as determined by the Calculation Agent using a volume-weighted method).

 

7

 

	 	 	 	 	 
	 

	 	Settlement Averaging Period:
	 	For any Exercisable Option and regardless of the Settlement Method applicable to
such Exercisable Option:
	 
	 	 	 	 
	 

	 	 	 	(i) if Counterparty has, on or prior to March 15, 2014, delivered a Notice of
Exercise to Dealer with respect to such Exercisable Option with a Conversion Date
occurring prior to March 15, 2014, the forty (40) consecutive Valid Days commencing
on and including the second Scheduled Valid Day following such Conversion Date; or
	 
	 	 	 	 
	 

	 	 	 	(ii) if Counterparty has, on or following March 15, 2014, delivered a Notice of
Exercise to Dealer with respect to such Exercisable Option with a Conversion Date
occurring on or following March 15, 2014, the forty (40) consecutive Valid Days
commencing on, and including, the forty-second (42nd) Scheduled Valid Day
immediately prior to the Expiration Date.
	 
	 	 	 	 
	 

	 	Settlement Date:
	 	For any Exercisable Option, the third Business Day immediately following the final
Valid Day of the Settlement Averaging Period for such Exercisable Option.
	 
	 	 	 	 
	 

	 	Settlement Currency:
	 	USD
	 
	 	 	 	 
	 

	 	Other Applicable Provisions:
	 	The provisions of Sections 9.1(c), 9.8, 9.9, 9.11, 9.12 and 10.5 of the Equity
Definitions will be applicable, except that all references in such provisions to
“Physically-settled” shall be read as references to “Share Settled”. “Share
Settled” in relation to any Option means that Net Share Settlement or Combination
Settlement is applicable to that Option.
	 
	 	 	 	 
	 

	 	Representation and Agreement:
	 	Notwithstanding Section 9.11 of the Equity Definitions, the parties acknowledge that
any Shares delivered to Counterparty shall be, upon delivery, subject to
restrictions and limitations arising from Counterparty’s status as issuer of the
Shares under applicable securities laws.
	 
	 	 	 	 
	3. Additional Terms applicable to
the Transaction:	 	 
	 
	 	 	 	 
	 

	 	Adjustments applicable to
the Transaction:	 	 
	 
	 	 	 	 
	 

	 	Potential Adjustment Events:
	 	Notwithstanding Section 11.2(e) of the Equity Definitions, a “Potential Adjustment
Event” means an occurrence of any event or condition, as set forth in Section
4.04(a), (b), (c), (d) or (e) of the Supplemental Indenture that would result in an
adjustment to the Conversion Rate of the Convertible Notes; provided that in no
event shall there be any adjustment hereunder as a result of an adjustment to the
Conversion Rate pursuant to Section 4.04(f) or (g) or Section 4.06 of the
Supplemental Indenture.

 

8

 

	 	 	 	 	 
	 

	 	Method of Adjustment:
	 	Calculation Agent Adjustment, and means that, notwithstanding Section 11.2(c) of the
Equity Definitions, upon any adjustment to the Conversion Rate of the Convertible
Notes pursuant to the Supplemental Indenture (other than Section 4.04(f) or (g) or
Section 4.06 of the Supplemental Indenture) or any adjustment pursuant to Section
4.05 of the Supplemental Indenture, the Calculation Agent will make a corresponding
adjustment to any one or more of the Strike Price, Number of Options, Option
Entitlement and any other variable relevant to the exercise, settlement or payment
for the Transaction; provided that if the Calculation Agent in good faith disagrees
with any adjustment to the Conversion Rate pursuant to Section 4.04(n) or Section
4.05 of the Supplemental Indenture, the Calculation Agent will determine the
corresponding adjustment to be made to any one or more of the Strike Price, Number
of Options, Option Entitlement and any other variable relevant to the exercise,
settlement or payment for the Transaction in a commercially reasonable manner.
	 
	 	 	 	 
	Extraordinary Events applicable
to the Transaction:	 	 
	 
	 	 	 	 
	 

	 	Merger Events:
	 	Applicable; provided that notwithstanding Section 12.1(b) of the Equity Definitions,
a “Merger Event” means the occurrence of any event or condition set forth in the
definition of “Merger Event” in Section 4.07(a) of the Supplemental Indenture.
	 
	 	 	 	 
	 

	 	Tender Offers:
	 	Applicable; provided that notwithstanding Section 12.1(d) of the Equity Definitions,
a “Tender Offer” means the occurrence of any event or condition set forth in Section
4.04(e) of the Indenture.
	 
	 	 	 	 
	 

	 	Consequence of Merger Events/Tender
Offers:
	 	Notwithstanding Section 12.2 and Section 12.3 of the Equity Definitions, upon the
occurrence of a Merger Event or a Tender Offer, the Calculation Agent shall make a
corresponding adjustment in respect of any adjustment under the Supplemental
Indenture to any one or more of the nature of the Shares, Strike Price, Number of
Options, Option Entitlement and any other variable relevant to the exercise,
settlement or payment for the Transaction; provided, however, that such adjustment
shall be made without regard to any adjustment to the Conversion Rate for the
issuance of additional shares as set forth in Section 4.06 of the Supplemental
Indenture; provided further that if, with respect to a Merger Event or Tender Offer,
(i) the consideration for the Shares includes (or, at the option of a holder of
Shares, may include) shares of an entity or person not organized under the laws of
the United States, any State thereof or the District of Columbia or (ii) the
Counterparty to the Transaction following such Merger Event or Tender Offer, will
not be the Issuer following such Merger Event or Tender Offer, then Cancellation and
Payment (Calculation Agent Determination) shall apply.
	 
	 	 	 	 
	 

	 	Nationalization, Insolvency or

Delisting:
	 	Cancellation and Payment (Calculation Agent Determination); provided that, in
addition to the provisions of Section 12.6(a)(iii) of the Equity Definitions, it
will also constitute a Delisting if the Exchange is located in the United States and
the Shares are not immediately re-listed, re-traded or re-quoted on any of the New
York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or
their respective successors); if the Shares are immediately re-listed, re-traded or
re-quoted on any of the New York Stock Exchange, The NASDAQ Global Select Market or
The NASDAQ Global Market (or their respective successors), such exchange or
quotation system shall thereafter be deemed to be the Exchange.

 

9

 

	 	 	 	 	 
	 

	 	Additional Disruption Events:	 	 
	 
	 	 	 	 
	 

	 	Change in Law:
	 	Applicable; provided that Section 12.9(a)(ii)(X) of the Equity Definitions is hereby
amended by replacing the word “Shares” with the phrase “Hedge Positions.”
	 
	 	 	 	 
	 

	 	Failure to Deliver:
	 	Applicable
	 
	 	 	 	 
	 

	 	Hedging Disruption:
	 	Applicable; provided that Section 12.9(a)(v) of the Equity Definitions is hereby
modified by inserting the following two phrases at the end of such Section:
	 
	 	 	 	 
	 

	 	 	 	“For the avoidance of doubt, the term “equity price risk” shall be deemed to
include, but shall not be limited to, stock price and volatility risk. And, for the
further avoidance of doubt, any such transactions or assets referred to in phrases
(A) or (B) above must be available on commercially reasonable pricing terms.”
	 
	 	 	 	 
	 

	 	Hedging Party:
	 	For all applicable Additional Disruption Events, Dealer.
	 
	 	 	 	 
	 

	 	Determining Party:
	 	For all applicable Extraordinary Events, Dealer.
	 
	 	 	 	 
	Non-Reliance:	 	Applicable
	 
	 	 	 	 
	Agreements and Acknowledgements
Regarding Hedging Activities:	 	Applicable
	 
	 	 	 	 
	Additional Acknowledgments:	 	Applicable
	 
	 	 	 	 
	4. Calculation Agent:	 	Dealer; provided that all determinations made by Dealer as Calculation Agent shall
be made in good faith and in a commercially reasonable manner. Following any
calculation or determination by Calculation Agent hereunder and a prior written
request by Counterparty, the Calculation Agent shall provide Counterparty a written
explanation of such calculation or determination including, where applicable, a
description of the methodology and the basis for such calculation or determination
in reasonable detail, it being understood that the Calculation Agent shall not be
obligated to disclose any proprietary models used by it for such calculation or
determination. No transferee of Dealer shall act as Calculation Agent without the
prior written consent of Counterparty, such consent not to be unreasonably withheld
or delayed.

5. Account Details:

	 	(a)	 	Account for payments to Counterparty:

Bank: JPMorgan Chase Bank, N.A., New York

ABA: 021000021

Acct: Exterran Holdings, Inc.

Acct No.: 737308817

 

10

 

Account for delivery of Shares to Counterparty:

To be provided by Counterparty.

	 	(b)	 	Account for payments to Dealer:

JPMorgan Chase Bank, National Association, New York

ABA: 021 000 021

Favour: JPMorgan Chase Bank, National Association — London

A/C: 0010962009 CHASUS33

Account for delivery of Shares from Dealer:

DTC 0060

6. Offices:

The Office of Counterparty for the Transaction is: Inapplicable, Counterparty is not a Multibranch
Party.

The Office of Dealer for the Transaction is: London

JPMorgan Chase Bank, National Association

London Branch

P.O. Box 161

60 Victoria Embankment

London EC4Y 0JP

England

7. Notices: For purposes of this Confirmation:

	 	(a)	 	Address for notices or communications to Counterparty:

Exterran Holdings, Inc.

16666 Northchase Drive

Houston, Texas 77060

Attention: Treasurer

Telephone No.: (281) 836-7000

Facsimile No.: (281) 836-8106

	 	(b)	 	Address for notices or communications to Dealer:

JPMorgan Chase Bank, National Association

4 New York Plaza, Floor 18

New York, NY 10004-2413

Attention: Mariusz Kwasnik

Title: Operations Analyst, EDG Corporate Marketing

Telephone No: (212) 623-7223

Facsimile No: (212) 623-7719

 

11

 

8. Representations and Warranties of Counterparty

Each of the representations and warranties of Counterparty set forth in Section 3 of the
Underwriting Agreement (the “Underwriting Agreement”) dated as of June 4, 2009 between Counterparty
and J.P. Morgan Securities Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Wachovia
Capital Markets, LLC and Credit Suisse Securities (USA) LLC as representative of the Underwriters
party thereto (the “Underwriters”), are true and correct and are hereby deemed to be repeated to
Dealer on the date hereof and on and as of the Premium Payment Date as if set forth herein.
Counterparty hereby further represents and warrants to Dealer that:

	 	(a)	 	Counterparty has all necessary corporate power and authority to execute,
deliver and perform its obligations in respect of this Transaction; such execution,
delivery and performance have been duly authorized by all necessary corporate action on
Counterparty’s part; and this Confirmation has been duly and validly executed and
delivered by Counterparty and constitutes its valid and binding obligation, enforceable
against Counterparty in accordance with its terms, subject to applicable bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and similar laws
affecting creditors’ rights and remedies generally, and subject, as to enforceability,
to general principles of equity, including principles of commercial reasonableness,
good faith and fair dealing (regardless of whether enforcement is sought in a
proceeding at law or in equity) and except that rights to indemnification and
contribution hereunder may be limited by federal or state securities laws or public
policy relating thereto.

	 	(b)	 	Neither the execution and delivery of this Confirmation nor the incurrence or
performance of obligations of Counterparty hereunder will conflict with or result in a
breach of the certificate of incorporation or by-laws (or any equivalent documents) of
Counterparty, or any applicable law or regulation, or any order, writ, injunction or
decree of any court or governmental authority or agency, or any agreement or instrument
to which Counterparty or any of its subsidiaries is a party or by which Counterparty or
any of its subsidiaries is bound or to which Counterparty or any of its subsidiaries is
subject, or constitute a default under, or result in the creation of any lien under,
any such agreement or instrument.

	 	(c)	 	No consent, approval, authorization, or order of, or filing with, any
governmental agency or body or any court is required in connection with the execution,
delivery or performance by Counterparty of this Confirmation, except such as have been
obtained or made and such as may be required under the Securities Act of 1933, as
amended (the “Securities Act”) or state securities laws.

	 	(d)	 	Counterparty is not and will not be required to register as an “investment
company” as such term is defined in the Investment Company Act of 1940, as amended.

	 	(e)	 	It is an “eligible contract participant” (as such term is defined in Section
1a(12) of the Commodity Exchange Act, as amended (the “CEA”)) because one or more of
the following is true:

Counterparty is a corporation, partnership, proprietorship, organization, trust or
other entity and:

	 	(A)	 	Counterparty has total assets in excess of USD 10,000,000;

	 	(B)	 	the obligations of Counterparty hereunder are guaranteed, or
otherwise supported by a letter of credit or keepwell, support or other
agreement, by an entity of the type described in Section 1a(12)(A)(i) through
(iv), 1a(12)(A)(v)(I), 1a(12)(A)(vii) or 1a(12)(C) of the CEA; or

	 	(C)	 	Counterparty has a net worth in excess of USD 1,000,000 and has
entered into this Agreement in connection with the conduct of Counterparty’s
business or to manage the risk associated with an asset or liability owned or
incurred or reasonably likely to be owned or incurred by Counterparty in the
conduct of Counterparty’s business.

	 	(f)	 	Each of it and its affiliates is not, on the date hereof, in possession of any
material non-public information with respect to Counterparty.

	 	(g)	 	Counterparty is entering into the Transaction for bona fide business purposes
and not for speculative purposes.

 

12

 

 

9. Other Provisions:

	 	(a)	 	Opinions. Counterparty shall deliver to Dealer an opinion of counsel,
dated as of the Trade Date and reasonably acceptable to Dealer in form and substance,
with respect to (i) due incorporation, existence and good standing of Counterparty in Delaware, (ii) Counterparty’s
qualifications as a foreign corporation and good standing in Texas, (iii) the due
authorization, execution and delivery of the Confirmation, and (iv) the absence of
conflict of the execution and delivery of the Confirmation with any material
agreement required to be filed as any exhibit to Counterparty’s Annual Report on
Form 10-K, Counterparty’s charter documents and any applicable law or regulation.
Delivery of such opinion to Dealer shall be a condition precedent for the purpose of
Section 2(a)(iii) of the Agreement with respect to each obligation of Dealer under
Section 2(a)(i) of the Agreement.

	 	(b)	 	Repurchase Notices. Counterparty shall, on any day on which
Counterparty effects any repurchase of Shares, promptly give Dealer a written notice of
such repurchase (a “Repurchase Notice”) on such day if following such repurchase, the
number of outstanding Shares as determined on such day is (i) less than 56.5 million
(in the case of the first such notice) or (ii) thereafter more than 5.4 million less
than the number of Shares included in the immediately preceding Repurchase Notice.
Counterparty agrees to indemnify and hold harmless Dealer and its affiliates and their
respective officers, directors, employees, affiliates, advisors, agents and controlling
persons (each, an “Indemnified Person”) from and against any and all losses (including
losses relating to Dealer’s hedging activities as a consequence of becoming, or of the
risk of becoming, a Section 16 “insider”, including without limitation, any forbearance
from hedging activities or cessation of hedging activities and any losses in connection
therewith with respect to this Transaction), claims, damages, judgments, liabilities
and expenses (including reasonable attorney’s fees), joint or several, which an
Indemnified Person may become subject to, as a result of Counterparty’s failure to
provide Dealer with a Repurchase Notice on the day and in the manner specified in this
paragraph, and to reimburse, within 30 days, upon written request, each of such
Indemnified Persons for any reasonable legal or other expenses incurred in connection
with investigating, preparing for, providing testimony or other evidence in connection
with or defending any of the foregoing. If any suit, action, proceeding (including any
governmental or regulatory investigation), claim or demand shall be brought or asserted
against the Indemnified Person as a result of Counterparty’s failure to provide Dealer
with a Repurchase Notice in accordance with this paragraph, such Indemnified Person
shall promptly notify Counterparty in writing, and Counterparty, upon request of the
Indemnified Person, shall retain counsel reasonably satisfactory to the Indemnified
Person to represent the Indemnified Person and any others Counterparty may designate in
such proceeding and shall pay the fees and expenses of such counsel related to such
proceeding. Counterparty shall not be liable for any settlement of any proceeding
contemplated by this paragraph that is effected without its written consent, but if
settled with such consent or if there be a final judgment for the plaintiff,
Counterparty agrees to indemnify any Indemnified Person from and against any loss or
liability by reason of such settlement or judgment. Counterparty shall not, without
the prior written consent of the Indemnified Person, effect any settlement of any
pending or threatened proceeding contemplated by this paragraph that is in respect of
which any Indemnified Person is or could have been a party and indemnity could have
been sought hereunder by such Indemnified Person, unless such settlement includes an
unconditional release of such Indemnified Person from all liability on claims that are
the subject matter of such proceeding on terms reasonably satisfactory to such
Indemnified Person. If the indemnification provided for in this paragraph is
unavailable to an Indemnified Person or insufficient in respect of any losses, claims,
damages or liabilities referred to therein, then Counterparty hereunder, in lieu of
indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or
payable by such Indemnified Person as a result of such losses, claims, damages or
liabilities. The remedies provided for in this paragraph (b) are not exclusive and
shall not limit any rights or remedies which may otherwise be available to any
Indemnified Party at law or in equity. The indemnity and contribution agreements
contained in this paragraph shall remain operative and in full force and effect
regardless of the termination of this Transaction.

	 	(c)	 	Regulation M. Counterparty is not on the date hereof engaged in a
distribution, as such term is used in Regulation M under the Exchange Act, of any
securities of Counterparty, other than the distribution of the Convertible Notes. Counterparty shall not, until the second
Scheduled Trading Day immediately following the Effective Date, engage in any such
distribution.

 

13

 

	 	(d)	 	No Manipulation. Counterparty is not entering into this Transaction to
create actual or apparent trading activity in the Shares (or any security convertible
into or exchangeable for the Shares) or to raise or depress or otherwise manipulate the
price of the Shares (or any security convertible into or exchangeable for the Shares)
or otherwise in violation of the Exchange Act.

	 	(e)	 	Transfer or Assignment. (i) Counterparty shall have the right to
transfer or assign its rights and obligations hereunder with respect to all, but not
less than all, of the Options hereunder (such Options, the “Transfer Options”);
provided that such transfer or assignment shall be subject to reasonable conditions
that Dealer may impose, including but not limited, to the following conditions:

(A) With respect to any Transfer Options, Counterparty shall not be released
from its notice and indemnification obligations pursuant to Section 9(b) or any
obligations under Section 9(m) or 9(r) of this Confirmation;

(B) Any Transfer Options shall only be transferred or assigned to a third party
that is a United States person (as defined in the Internal Revenue Code of 1986,
as amended);

(C) Such transfer or assignment shall be effected on terms, including any
reasonable undertakings by such third party (including, but not limited to, an
undertaking with respect to compliance with applicable securities laws in a
manner that, in the reasonable judgment of Dealer, will not expose Dealer to
material risks under applicable securities laws) and execution of any
documentation and delivery of legal opinions with respect to securities laws and
other matters by such third party and Counterparty, as are requested and
reasonably satisfactory to Dealer;

(D) Dealer will not, as a result of such transfer and assignment, be required to
pay the transferee on any payment date an amount under Section 2(d)(i)(4) of the
Agreement greater than an amount that Dealer would have been required to pay to
Counterparty in the absence of such transfer and assignment;

(E) An Event of Default, Potential Event of Default or Termination Event will
not occur as a result of such transfer and assignment;

(F) Without limiting the generality of clause (B), Counterparty shall cause the
transferee to make such Payee Tax Representations and to provide such tax
documentation as may be reasonably requested by Dealer to permit Dealer to
determine that results described in clauses (D) and (E) will not occur upon or
after such transfer and assignment; and

(G) Counterparty shall be responsible for all reasonable costs and expenses,
including reasonable counsel fees, incurred by Dealer in connection with such
transfer or assignment.

(ii) Dealer may, without Counterparty’s consent, transfer or assign all or any part
of its rights or obligations under the Transaction to any third party with a rating
for its long term, unsecured and unsubordinated indebtedness equal to or better than
the lesser of (x) the credit rating of Dealer at the time of the transfer and (y) A-
by Standard and Poor’s Rating Group, Inc. or its successor (“S&P”), or A3 by Moody’s
Investor Service, Inc. (“Moody’s”) or, if either S&P or Moody’s ceases to rate such
debt, at least an equivalent rating or better by a substitute rating agency mutually
agreed by Counterparty and Dealer. If at any time at which (1) the Section 16
Percentage exceeds 7.5%, (2) the Option Equity Percentage exceeds 14.5%, or (3) the
Share Amount exceeds the Post-Effective Limit (if any applies), Dealer is unable
after using its commercially reasonable efforts to effect a transfer or assignment
of Options to a third party on pricing terms reasonably acceptable to Dealer and
within a time period reasonably acceptable to Dealer such that (1) the Section 16
Percentage will be equal to or less than 7.5%, (2) the Option Equity Percentage will
be equal to or less than 14.5%, and (3) the Share Amount will be equal to or less
than any such Post-Effective Limit, then Dealer may designate any Exchange Business
Day as an Early Termination Date with respect to a portion of the Transaction

 

14

 

(the
“Terminated Portion”), such that following such partial termination (1) the Section 16 Percentage will be equal to or less than
7.5%, (2) the Option Equity Percentage will be equal to or less than 14.5%, and (3)
the Share Amount will be equal to or less than such Post-Effective Limit. In the
event that Dealer so designates an Early Termination Date with respect to a
Terminated Portion, a payment shall be made pursuant to Section 6 of the Agreement
as if (1) an Early Termination Date had been designated in respect of a Transaction
having terms identical to this Transaction and a Number of Options equal to the
number of Options underlying the Terminated Portion, (2) Counterparty shall be the
sole Affected Party with respect to such partial termination and (3) the Terminated
Portion shall be the sole Affected Transaction (and, for the avoidance of doubt, the
provisions of Section 9(k) shall apply to any amount that is payable by Dealer to
Counterparty pursuant to this sentence as if Counterparty was not the Affected
Party). The “Section 16 Percentage” as of any day is the fraction, expressed as a
percentage, (A) the numerator of which is the number of Shares that Dealer and each
person subject to aggregation of Shares with Dealer under Section 13 or Section 16
of the Exchange Act and rules promulgated thereunder directly or indirectly
beneficially own (as defined under Section 13 or Section 16 of the Exchange Act and
rules promulgated thereunder) and (B) the denominator of which is the number of
Shares outstanding. The “Option Equity Percentage” as of any day is the fraction,
expressed as a percentage, (A) the numerator of which is the sum of (x) the product
of the Number of Options and the Option Entitlement and (y) the aggregate number of
Shares underlying any other call option transaction sold by Dealer to Counterparty,
and (B) the denominator of which is the number of Shares outstanding. The “Share
Amount” as of any day is the number of Shares that Dealer and any person whose
ownership position would be aggregated with that of Dealer (Dealer or any such
person, a “Dealer Person”) under any law, rule, regulation or regulatory order that
for any reason becomes applicable to ownership of Shares after the Trade Date
(“Applicable Laws”), owns, beneficially owns, constructively owns, controls, holds
the power to vote or otherwise meets a relevant definition of ownership of under the
Applicable Laws, as determined by Dealer in its reasonable discretion. The
“Post-Effective Limit” means (x) the minimum number of Shares that would give rise
to reporting or registration obligations or other requirements (including obtaining
prior approval from any person or entity) of a Dealer Person, or would result in an
adverse effect on a Dealer Person, under the Applicable Laws, as determined by
Dealer in its reasonable discretion, minus (y) 1% of the number of Shares
outstanding.

(iii) Notwithstanding any other provision in this Confirmation to the contrary
requiring or allowing Dealer to purchase, sell, receive or deliver any Shares or
other securities to or from Counterparty, Dealer may designate any of its affiliates
to purchase, sell, receive or deliver such Shares or other securities and otherwise
to perform Dealer’s obligations in respect of this Transaction and any such designee
may assume such obligations. Dealer shall be discharged of its obligations to
Counterparty to the extent of any such performance.

	 	(f)	 	Staggered Settlement. If upon advice of counsel with respect to
applicable legal and regulatory requirements, including any requirements relating to
Dealer’s hedging activities hereunder, Dealer reasonably determines that it would not
be practicable or advisable to deliver, or to acquire Shares to deliver, any or all of
the Shares to be delivered by Dealer on the Settlement Date for the Transaction, Dealer
may, by notice to Counterparty on or prior to any Settlement Date (a “Nominal
Settlement Date”), elect to deliver the Shares on two or more dates (each, a “Staggered
Settlement Date”) as follows:

(i) in such notice, Dealer will specify to Counterparty the related Staggered
Settlement Dates (the first of which will be such Nominal Settlement Date and the
last of which will be no later than the twentieth (20th) Exchange Business Day
following such Nominal Settlement Date) and the number of Shares that it will
deliver on each Staggered Settlement Date;

(ii) the aggregate number of Shares that Dealer will deliver to Counterparty
hereunder on all such Staggered Settlement Dates will equal the number of Shares
that Dealer would otherwise be required to deliver on such Nominal Settlement Date;
and

 

15

 

(iii) if the Net Share Settlement terms or the Combination Settlement terms set
forth above were to apply on the Nominal Settlement Date, then the Net Share
Settlement terms or the Combination Settlement terms, as applicable, will apply on
each Staggered Settlement Date, except that the Shares deliverable pursuant to such
terms on the Nominal Settlement Date will be allocated among such Staggered
Settlement Dates as specified by Dealer in the notice referred to in clause (i)
above.

	 	(g)	 	Role of Agent. Each party agrees and acknowledges that (i) J.P. Morgan
Securities Inc., an affiliate of Dealer (“JPMSI”), has acted solely as agent and not as
principal with respect to this Transaction and (ii) JPMSI has no obligation or
liability, by way of guaranty, endorsement or otherwise, in any manner in respect of
this Transaction (including, if applicable, in respect of the settlement thereof). Each
party agrees it will look solely to the other party (or any guarantor in respect
thereof) for performance of such other party’s obligations under this Transaction.

	 	(h)	 	Additional Termination Events. Notwithstanding anything to the
contrary in this Confirmation if an event of default with respect to Counterparty shall
occur under the terms of the Convertible Notes as set forth in Section 5.01 of the
Supplemental Indenture or under Section 6.01 of the Base Indenture, as modified by
Section 5.01 of the Supplemental Indenture, which event of default results in the
Convertible Notes becoming due and payable before their stated maturity, then such
event of default shall constitute an Additional Termination Event applicable to the
Transaction and, with respect to such event of default (A) Counterparty shall be deemed
to be the sole Affected Party and the Transaction shall be the sole Affected
Transaction and (B) Dealer shall be the party entitled to designate an Early
Termination Date pursuant to Section 6(b) of the Agreement.

(i)      Amendments to Equity Definitions.

(i) Section 12.6(a)(ii) of the Equity Definitions is hereby amended by (1) deleting
from the fourth line thereof the word “or” after the word “official” and inserting a
comma therefor, and (2) deleting the semi-colon at the end of subsection (B) thereof
and inserting the following words therefor “or (C) at Dealer’s option, the
occurrence of any of the events specified in Section 5(a)(vii)(1) through (9) of the
ISDA Master Agreement with respect to that Issuer.”

(ii) Section 12.9(b)(i) of the Equity Definitions is hereby amended by (1) replacing
“either party may elect” with “Dealer may elect” and (2) replacing “notice to the
other party” with “notice to Counterparty” in the first sentence of such section.

	 	(j)	 	No Set-Off. Neither party shall have the right to set off any
obligation that it may have to the other party under this Transaction against any
obligation such other party may have to it, whether arising under the Agreement, this
Confirmation or any other agreement between the parties hereto, by operation of law or
otherwise.

	 	(k)	 	Alternative Calculations and Payment on Early Termination and on Certain
Extraordinary Events. If in respect of this Transaction, an amount is payable by
Dealer to Counterparty (i) pursuant to Section 12.7 or Section 12.9 of the Equity
Definitions or (ii) pursuant to Section 6(d)(ii) of the Agreement (a “Payment
Obligation”), Counterparty may request Dealer to satisfy any such Payment Obligation by
the Share Termination Alternative (as defined below) (except that Counterparty shall
not make such an election in the event of a Nationalization, Insolvency, Merger Event
or Tender Offer, in each case, in which the consideration to be paid to holders of
Shares consists solely of cash, or an Event of Default in which Counterparty is the
Defaulting Party or a Termination Event in which Counterparty is the Affected Party,
other than an Event of Default of the type described in Section 5(a)(iii), (v), (vi),
(vii) or (viii) of the Agreement or a Termination Event of the type described in
Section 5(b) of the Agreement in each case that resulted from an event or events
outside Counterparty’s control) and shall give irrevocable telephonic notice to Dealer,
confirmed in writing within one Scheduled Trading Day, no later than 12:00 p.m. (New
York City time) on the Merger Date, the Tender Offer Date, the Announcement Date (in
the case of Nationalization, Insolvency or Delisting), the Early Termination Date or
date of cancellation, as applicable; provided that if Counterparty does not validly
request Dealer to satisfy

 

16

 

its Payment Obligation by the Share Termination Alternative, Dealer shall
have the right, in its reasonable discretion, to satisfy its Payment Obligation by
the Share Termination Alternative, notwithstanding Counterparty’s election to the
contrary. In calculating any amounts under Section 6(e) of the Agreement,
notwithstanding anything to the contrary in the Agreement, (1) separate amounts
shall be calculated as set forth in Section 6(e) with respect to (i) this
Transaction and (ii) all other Transactions, and (2) such separate amounts shall be
payable pursuant to Section 6(d)(ii) of the Agreement.

	 	 	 	 	 
	 

	 	Share Termination Alternative:
	 	Applicable and means that Dealer shall deliver to Counterparty the Share
Termination Delivery Property on, or within a commercially reasonable
period of time after, the date when the Payment Obligation would
otherwise be due pursuant to Section 12.7 or 12.9 of the Equity
Definitions or Section 6(d)(ii) and 6(e) of the Agreement, as applicable
(the “Share Termination Payment Date”), in satisfaction of the Payment
Obligation in the manner reasonably requested by Counterparty free of
payment.
	 
	 	 	 	 
	 

	 	Share Termination Delivery Property:
	 	A number of Share Termination Delivery Units, as calculated by the
Calculation Agent, equal to the Payment Obligation divided by the Share
Termination Unit Price. The Calculation Agent shall adjust the Share
Termination Delivery Property by replacing any fractional portion of a
security therein with an amount of cash equal to the value of such
fractional security based on the values used to calculate the Share
Termination Unit Price.
	 
	 	 	 	 
	 

	 	Share Termination Unit Price:
	 	The value to Dealer of property contained in one Share Termination
Delivery Unit, as determined by the Calculation Agent in its discretion
by commercially reasonable means and notified by the Calculation Agent
to Dealer at the time of notification of the Payment Obligation. For the
avoidance of doubt, the parties agree that in determining the Share
Termination Delivery Unit Price the Calculation Agent may consider the
purchase price paid in connection with the purchase of Share Termination
Delivery Property.
	 
	 	 	 	 
	 

	 	Share Termination Delivery Unit:
	 	One Share or, if a Merger Event has occurred and a corresponding
adjustment to this Transaction has been made, a unit consisting of the
number or amount of each type of property received by a holder of one
Share (without consideration of any requirement to pay cash or other
consideration in lieu of fractional amounts of any securities) in such
Merger Event, as determined by the Calculation Agent.
	 
	 	 	 	 
	 

	 	Failure to Deliver:
	 	Applicable
	 
	 	 	 	 
	 

	 	Other applicable provisions:
	 	If Share Termination Alternative is applicable, the provisions of
Sections 9.8, 9.9, 9.11, 9.12 and 10.5 (as modified above) of the Equity
Definitions will be applicable, except that all references in such
provisions to “Physically-settled” shall be read as references to “Share
Termination Settled” and all references to “Shares” shall be read as
references to “Share Termination Delivery Units”. “Share Termination
Settled” in relation to this Transaction means that Share Termination
Alternative is applicable to this Transaction.

 

17

 

	 	(l)	 	Waiver of Jury Trial. Each party waives, to the fullest extent
permitted by applicable law, any right it may have to a trial by jury in respect of any
suit, action or proceeding relating to this Transaction. Each party (i) certifies that
no representative, agent or attorney of either party has represented, expressly or
otherwise, that such other party would not, in the event of such a suit, action or
proceeding, seek to enforce the foregoing waiver and (ii) acknowledges that it and the
other party have been induced to enter into this Transaction, as applicable, by, among
other things, the mutual waivers and certifications provided herein.

	 	(m)	 	Registration. Counterparty hereby agrees that if, in the good faith
reasonable judgment of Dealer (A) the Shares acquired by Dealer for the purpose of
hedging its obligations pursuant to this Transaction (the “Hedge Shares”) or (B) any
Early Unwind Shares delivered to Dealer pursuant to Section 9(s) (any such Hedge Shares
or Early Unwind Shares, “Restricted Shares”) cannot be sold in the public market by
Dealer without registration under the Securities Act, Counterparty shall, at its
election, either (i) in order to allow Dealer to sell the Restricted Shares in a
registered offering, make available to Dealer an effective registration statement under
the Securities Act and enter into an agreement, in form and substance satisfactory to
Dealer, substantially in the form of an underwriting agreement for a registered
secondary offering; provided, however, that if Dealer, in its sole reasonable
discretion, is not satisfied with access to due diligence materials, the results of its
due diligence investigation, or the procedures and documentation for the registered
offering referred to above, then clause (ii) or clause (iii) of this paragraph shall
apply at the election of Counterparty, (ii) in order to allow Dealer to sell the
Restricted Shares in a private placement, enter into a private placement agreement
substantially similar to private placement purchase agreements customary for private
placements of equity securities, in form and substance satisfactory to Dealer (in which
case, the Calculation Agent shall make any adjustments to the terms of this Transaction
that are necessary, in its reasonable judgment, to compensate Dealer for any discount
from the public market price of the Shares incurred on the sale of Restricted Shares in
a private placement), or (iii) purchase the Restricted Shares from Dealer at the
Reference Price on such Exchange Business Days, and in the amounts, requested by
Dealer.

	 	(n)	 	Tax Disclosure. Effective from the date of commencement of discussions
concerning the Transaction, Counterparty and each of its employees, representatives, or
other agents may disclose to any and all persons, without limitation of any kind, the
tax treatment and tax structure of the Transaction and all materials of any kind
(including opinions or other tax analyses) that are provided to Counterparty relating
to such tax treatment and tax structure.

	 	(o)	 	Right to Extend. Dealer may postpone, in whole or in part, any
Settlement Date or any other date of valuation or delivery by Dealer or add additional
Settlement Dates or any other date of valuation or delivery, with respect to some or
all of the Options hereunder, if Dealer reasonably determines, in its discretion, that
such extension is reasonably necessary or appropriate to preserve Dealer’s hedging or
hedge unwind activity hereunder in light of existing liquidity conditions or to enable
Dealer to effect purchases of Shares in connection with its hedging, hedge unwind or
settlement activity hereunder in a manner that would, if Dealer were Counterparty or an
affiliated purchaser of Counterparty, be in compliance with applicable legal,
regulatory or self-regulatory requirements, or with related policies and procedures
applicable to Dealer.

	 	(p)	 	Status of Claims in Bankruptcy. Dealer acknowledges and agrees that
this Confirmation is not intended to convey to Dealer rights against Counterparty with
respect to the Transaction that are senior to the claims of common stockholders of Counterparty in any United States
bankruptcy proceedings of Counterparty; provided that nothing herein shall limit or
shall be deemed to limit Dealer’s right to pursue remedies in the event of a breach
by Counterparty of its obligations and agreements with respect to the Transaction;
provided, further, that nothing herein shall limit or shall be deemed to limit
Dealer’s rights in respect of any transactions other than the Transaction.

 

18

 

	 	(q)	 	Securities Contract; Swap Agreement. The parties hereto intend for:
(a) the Transaction to be a “securities contract” and a “swap agreement” as defined in
the Bankruptcy Code (Title 11 of the United States Code) (the “Bankruptcy Code”), and
the parties hereto to be entitled to the protections afforded by, among other Sections,
Sections 362(b)(6), 362(b)(17), 546(e), 546(g), 555 and 560 of the Bankruptcy Code; (b)
a party’s right to liquidate the Transaction and to exercise any other remedies upon
the occurrence of any Event of Default under the Agreement with respect to the other
party to constitute a “contractual right” as described in the Bankruptcy Code; and (c)
each payment and delivery of cash, securities or other property hereunder to constitute
a “margin payment” or “settlement payment” and a “transfer” as defined in the
Bankruptcy Code.

	 	(r)	 	Notice of Merger Consideration. Counterparty covenants and agrees that,
as promptly as practicable following the public announcement of any consolidation,
merger and binding share exchange to which Counterparty is a party, or any sale of all
or substantially all of Counterparty’s assets, in each case pursuant to which the
Shares will be converted into cash, securities or other property, Counterparty shall
notify Dealer in writing of the types and amounts of consideration that holders of
Shares have elected to receive upon consummation of such transaction or event (the date
of such notification, the “Consideration Notification Date”); provided that in no event
shall the Consideration Notification Date be later than the date on which such
transaction or event is consummated.

	 	(s)	 	Early Unwind. (i) In the event the sale of the “Underwritten
Securities” (as defined in the Underwriting Agreement) is not consummated with the
Underwriters for any reason, or if Counterparty fails to deliver to Dealer opinions of
counsel as required pursuant to Section 9(a), in each case by 5:00 p.m. (New York City
time) on the Premium Payment Date, or such later date as agreed upon by the parties
(the Premium Payment Date or such later date, the “Early Unwind Date”), the Transaction
shall automatically terminate (the “Early Unwind”), on the Early Unwind Date and (i)
the Transaction and all of the respective rights and obligations of Dealer and
Counterparty under the Transaction shall be cancelled and terminated and (ii) each
party shall be released and discharged by the other party from and agrees not to make
any claim against the other party with respect to any obligations or liabilities of the
other party arising out of and to be performed in connection with the Transaction
either prior to or after the Early Unwind Date; provided that Counterparty shall
reimburse Dealer for any costs or expenses (including market losses) relating to the
unwinding of its hedging activities in connection with the Transaction (including any
loss or cost incurred as a result of terminating, liquidating, obtaining or
reestablishing any hedge or related trading position of Dealer or one or more of its
affiliates in connection with the Transaction). The amount of any such reimbursement
shall be determined by Dealer in its sole good faith discretion. Dealer shall notify
Counterparty of such amount and Counterparty shall pay such amount in immediately
available funds on the Early Unwind Date. Each of Dealer and Counterparty represent
and acknowledge to the other that, subject to the proviso included in this Section,
upon an Early Unwind, all obligations with respect to the Transaction shall be deemed
fully and finally discharged.

 

19

 

(ii) If an amount is payable by Counterparty to Dealer pursuant to Section 9(s)(i)
(a “Reimbursement Obligation”), Counterparty shall have the right, in its sole
discretion, to satisfy any such Reimbursement Obligation by delivering to Dealer, on
the Exchange Business Day immediately following the Early Unwind Date, the Early
Unwind Shares (as defined below) in satisfaction of such Reimbursement Obligation in
the manner reasonably requested by Dealer free of payment. The “Early Unwind
Shares” shall be a number of Shares equal to the Reimbursement Obligation otherwise
payable under Section 9(s)(i) divided by the value to Dealer per Share on the date
such Shares are to be delivered as Early Unwind Shares (the “Early Unwind
Share Price”), as determined by the Calculation Agent in its discretion using
commercially reasonable means, together with cash in lieu of any fractional Shares
based on the Early Unwind Share Price. The Calculation Agent shall notify
Counterparty of the Early Unwind Share Price at the time of notification of the
Reimbursement Obligation. If such Early Unwind Shares are Restricted Shares as set
forth in Section 9(m), the Early Unwind Share Price may reflect, in the Calculation
Agent’s judgment, a discount applicable to such Early Unwind Shares. If such Early
Unwind Shares are not Restricted Shares as set forth in Section 9(m), the Early
Unwind Price shall be Relevant Price on the Early Unwind Date. Counterparty shall
give irrevocable telephonic notice, confirmed in writing within one Scheduled
Trading Day, to Dealer of its election to satisfy any Reimbursement Obligation by
delivery of Early Unwind Shares pursuant to this Section 9(s)(ii) no later than 6:00
p.m. (New York City time) on the Early Unwind Date.

(iii) Notwithstanding any other provision of this Confirmation or the Agreement, in
no event will Counterparty be required to deliver more than the Number of Shares in
the aggregate to Dealer pursuant to this Section 9(s). In the event Counterparty
shall not have delivered the full number of Shares otherwise applicable as a result
of the foregoing sentence (such deficit, the “Deficit Shares”), Counterparty shall
be continually obligated to deliver, from time to time until the full number of
Deficit Shares have been delivered pursuant to this Section 9(s), Shares when, and
to the extent, that (A) Shares are repurchased, acquired or otherwise received by
Counterparty or any of its subsidiaries after the Trade Date (whether or not in
exchange for cash, fair value or any other consideration), (B) authorized and
unissued Shares reserved for issuance in respect of other transactions prior to such
date which prior to the relevant date become no longer so reserved and (C)
Counterparty additionally authorizes any unissued Shares that are not reserved for
other transactions. Counterparty shall immediately notify Dealer of the occurrence
of any of the foregoing events (including the number of Shares subject to clause
(A), (B) or (C) and the corresponding number of Shares to be delivered) and promptly
deliver the Applicable Percentage of the aggregate number of such Shares thereafter.

	 	(t)	 	Payment by Counterparty. In the event that (i) an Early Termination
Date occurs or is designated with respect to the Transaction as a result of a
Termination Event or an Event of Default (other than an Event of Default arising under
Section 5(a)(ii) or 5(a)(iv) of the Agreement) and, as a result, Counterparty owes to
Dealer an amount calculated under Section 6(e) of the Agreement, or (ii) Counterparty
owes to Dealer, pursuant to Section 12.7 or Section 12.9 of the Equity Definitions, an
amount calculated under Section 12.8 of the Equity Definitions, such amount shall be
deemed to be zero.

 

20

 

Please confirm that the foregoing correctly sets forth the terms of our agreement by executing
this Confirmation and returning it to EDG Confirmation Group, J.P. Morgan Securities Inc., 277 Park
Avenue, 11th Floor, New York, NY 10172-3401, or by fax to (212) 622 8519.

	 	 	 	 	 
	 	Very truly yours,

J.P. Morgan Securities Inc., as agent for

JPMorgan Chase Bank, National Association

 	 
	 	By:   	 /s/
Michael O’Donovan	 
	 	 	Authorized Signatory 	 
	 	 	Name: Michael O’Donovan	 

	 	 	 	 	 
	Accepted and confirmed

as of the Trade Date:

Exterran Holdings, Inc.

 	 	 
	By:  	 /s/
J. Michael Anderson	 	 
	 	Authorized Signatory 	 	 
	 	Name: J. Michael Anderson	 	 

JPMorgan Chase Bank, National Association

Organised under the laws of the United States as a National Banking Association

Main Office 1111 Polaris Parkway, Columbus, Ohio 43271

Registered as a branch in England & Wales branch No. BR000746

Registered Branch Office 125 London Wall, London EC2Y 5AJ

Authorised and regulated by the Financial Services Authority

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]